

CITATION REPORT

List of articles citing

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

DOI: 10.1016/s0140-6736(03)14285-7
Lancet, The, 2003, 362, 777-81.

Source: <https://exaly.com/paper-pdf/35515230/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2328	What's new in Heart failure. 2002 , 30, 1-4		
2327	Cardiac resynchronization therapy with or without an implantable defibrillator: only indicated when everything else has failed?. 2003 , 7, 421-9		
2326	More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, VALHEFT, HOPE-TOO and SYST-EUR2). 2003 , 17, 747-50		20
2325	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003 , 362, 759-66	40	1506
2324	The CHARM programme. <i>Lancet, The</i> , 2003 , 362, 1675-6; author reply 1678-9	40	1
2323	The CHARM programme. <i>Lancet, The</i> , 2003 , 362, 1677; author reply 1678-9	40	
2322	Effect of ultrasound screening on the rate of first operative procedures for developmental hip dysplasia in Germany. <i>Lancet, The</i> , 2003 , 362, 1883-7	40	92
2321	What a CHARMer!. <i>Lancet, The</i> , 2003 , 362, 1887	40	
2320	Angiotensin receptor blockers in heart failure. 2003 , 4, 171-5		4
2319	Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. 2003 , 5, 697-704		11
2318	Diastolic heart failure. 2003 , 327, 1181-2		11
2317	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. 2004 , 110,		59
2316	Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?. 2004 , 25, 357-8		6
2315	Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 2004 , 25, 1920-6		37
2314	Clinical implications of blockade of the renin-angiotensin system in management of hypertension. 2004 , 143, 105-16		4
2313	Diastolic heart failure: recognition, diagnosis and management. 2004 , 5, 1745-54		4
2312	All antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. 2004 , 20, 279-93		17

2311	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. 2004 , 25, 1454-70	176
2310	Obesity and hypertension-induced restrictive cardiomyopathy: a harbinger of things to come. 2004 , 43, 911-7	8
2309	Author's Reply. 2004 , 38, 2176-2177	
2308	Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 2004 , 110, 2180-3	203
2307	Conclusions on the management of heart failure. 2004 , 5 Suppl 1, S34-6	
2306	AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. 2004 , 43, 686-91	98
2305	Atrial fibrillation and heart failure: natural history and pharmacological treatment. 2004 , 5 Suppl 1, S5-19	76
2304	Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?. 2004 , 110, 3281-8	58
2303	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004 , 110, 588-636	1550
2302	Valsartan. 2004 , 2, 67-101	
2301	Diagnosis and management of chronic heart failure: how to reestablish a key role for the primary care physician?. 2004 , 59, 300-3	
2300	Angiotensin receptor blockers and myocardial infarction. 2004 , 329, 1248-9	153
2299	Heart failure with preserved ejection fraction. Diastolic dysfunction, subtle systolic dysfunction, systolic-ventricular and arterial stiffening, or misdiagnosis?. 2004 , 64, 9-11	9
2298	Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. 2004 , 25, 1214-20	263
2297	The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure. 2004 , 13, 245-53	1
2296	The use of angiotensin receptor blockers in the treatment of chronic heart failure. 2004 , 44, 718-24	2
2295	Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. 2004 , 43, 993-1002	928
2294	Angiotensin inhibition in heart failure. 2004 , 5 Suppl 1, S17-22	12

2293	Candesartan for the treatment of hypertension and heart failure. 2004 , 5, 1589-97	11
2292	Angiotensin II receptor blockers in older patients. 2004 , 13, 197-205; quiz 206-7	7
2291	Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. 2004 , 110, 2618-26	282
2290	Can natriuretic peptides be used for the diagnosis of diastolic heart failure?. 2004 , 6, 281-7	58
2289	Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy. 2004 , 6, 801-6	23
2288	Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme. 2004 , 10, 114-116	1
2287	Nesiritide for the treatment of diastolic dysfunction. 2004 , 10, 154-7	2
2286	Left ventricular diastolic dysfunction: risks, identification, and treatment. 2004 , 19, 31-6	
2285	Elevations in serum creatinine concentration: concerning or reassuring?. 2004 , 24, 697-702; discussion 702-3	21
2284	[Dyspnea and normal systolic function]. 2004 , 29, 602-8	2
2283	Is too much neurohormonal blockade harmful?. 2004 , 6, 169-75	4
2282	Is heart failure different on the two continents (North America and Europe)?. 2004 , 6, 182-8	1
2281	Antihypertensive drugs and the heart. 2004 , 6, 409-15	2
2280	Anemia and heart failure. 2004 , 1, 176-82	26
2279	Clinical trials report. 2004 , 6, 45-50	6
2278	Diastolic heart failure: the forgotten manifestation of hypertensive heart disease. 2004 , 6, 164-70	7
2277	Diastolic Dysfunction. 2004 , 6, 61-68	4
2276	The Hypertension Guidelines of the Seventh Joint National Committee. 2004 , 11, 55-59	1

2275	Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. 2004 , 11, 65-73	4
2274	Similarities and Differences between Angiotensin II Type 1 Receptor Antagonists. 2004 , 11, 117-121	
2273	Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?. 2004 , 4, 345-53	6
2272	Appearances can deceive: even brave hearts can fail. 2004 , 25, 1181-2	
2271	Left ventricular diastolic dysfunction and diastolic heart failure. 2004 , 55, 373-94	219
2270	La protecci3n card3aca es la estrategia prioritaria de prevenci3n cardiovascular en hipertensi3n arterial. 2004 , 21, 187-196	
2269	Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. 2004 , 88, 1257-71	79
2268	Avances en el tratamiento de la insuficiencia card3aca. 2004 , 123, 149-155	
2267	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. 2004 , 57, 1213-1232	1
2266	[Hypertension and metabolic syndrome]. 2004 , 123, 707-11	6
2265	Bases y evidencias cl3nicas de los efectos de los nuevos tratamientos farmacol3gicos en la insuficiencia card3aca. 2004 , 57, 447-464	5
2264	The global epidemiology of heart failure. 2004 , 88, 1135-43, ix	64
2263	Rationale and Clinical Evidence for the Effects of New Pharmacological Treatments for Heart Failure. 2004 , 57, 447-464	1
2262	Diagnosis and Therapy for Diastolic Heart Failure. 2004 , 57, 570-575	
2261	Uncovering a hidden epidemic: a study of the current burden of heart failure in Australia. 2004 , 13, 266-73	44
2260	News from the European Society of Cardiology congress in Vienna, August 30 to September 3, 2003. 2004 , 43, 691-7	
2259	Reply. 2004 , 43, 1333-1334	0
2258	Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. 2004 , 43, 2036-43	105

2257	Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. 2004 , 44, 1025-9	92
2256	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). 2004 , 44, E1-E211	830
2255	Renal insufficiency as an independent predictor of mortality among women with heart failure. 2004 , 44, 1593-600	70
2254	The year in heart failure. 2004 , 44, 2398-405	9
2253	A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. 2004 , 10, 193-9	22
2252	2003: The year in heart failure. 2004 , 10, 1-3	
2251	Angiotensin Vol. II. 2004 ,	1
2250	Diagnóstico y tratamiento de la insuficiencia cardíaca diastólica. 2004 , 57, 570-575	5
2249	Clinical practice. Diastolic heart failure. 2004 , 351, 1097-105	412
2248	Documentation forms for patients with asthma: an evaluation. 2004 , 38, 2170-1	0
2247	AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. 2004 , 2, 891-902	3
2246	Commentary 2. 2004 , 8, 98-100	
2245	Thérapeutique diurétique. 2004 , 1, 73-111	
2244	From CONSENSUS to CHARM--how do ACEI and ARB produce clinical benefits in CHF?. 2004 , 94, 137-41	13
2243	Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. 2004 , 97, 345-8	7
2242	Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. 2004 , 148, 52-61	343
2241	Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure. 2004 , 148, 710-7	37
2240	New insights into diastolic heart failure: role of diabetes mellitus. 2004 , 116 Suppl 5A, 64S-75S	65

2239	Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade. 2004 , 6, 699-705	2
2238	Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?. 2004 , 6, 425-7	10
2237	Reflections in hypertension: heart failure and hypertension: the diastolic dilemma. 2004 , 6, 647-50	4
2236	Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction. 2004 , 6, 315-23; quiz 324-5	4
2235	[Diagnostic and therapeutic progress. Venous thromboembolism, cardiac insufficiency and radio contrast agents]. 2004 , 33, 623-30	1
2234	Actualit�s sur les grands essais cliniques en cardiologie. 2004 , 33, 1064-1072	
2233	[New horizons in the management of heart failure]. 2004 , 33, 1118-20	
2232	Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. 2004 , 30, 487-96	212
2231	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). 2004 , 44, 671-719	940
2230	Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. 2004 , 26, 460-72	15
2229	Valsartan. 2004 , 2, 67-101	2
2228	Guidelines for the diagnosis and management of heart failure. 2004 , 11, 467-72	11
2227	Bibliography. Current world literature. Molecular genetics. 2004 , 19, 278-87	
2226	Old antihypertensives and new diabetes. 2004 , 22, 1453-8	121
2225	Developments in Cardiology�2004. 2004 , 34, 234-236	
2224	European Society of Cardiology Congress 2003. 2004 , 34, 39-40	
2223	Treatment of heart failure with preserved systolic function: a review of the evidence. 2004 , 6, h61-h66	
2222	Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. 2004 , 22, 2253-61	146

2221	2003: The year in heart failure*1. 2004 , 10, 1-3	23
2220	Rationale, design, and organization of the Diastolic Heart Failure Assessment Study in Tohoku District (DIAST). 2004 , 68, 660-4	7
2219	Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. 2004 , 141, 693-704	140
2218	Management of Heart Failure Patients with Preserved Left Ventricular Ejection Fraction. 2005 , 6, S15-S16	
2217	Review: Effective Implementation of the New ESC Guidelines for the Management of Chronic Heart Failure in Routine Clinical Practice. 2005 , 6, S6-S10	1
2216	Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies. 2005 , 13, 297-303	10
2215	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. 2005 , 14, 435-41	28
2214	Introduction. 2005 , 6, S1-S1	2
2213	The Cardiologist's View: Prevention of Macrovascular Complications. 2005 , 313-323	
2212	The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. 2005 , 23, S9-S17	138
2211	Early recognition and treatment of hypertensive heart disease. 2005 , 20, 282-9	14
2210	Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. 2005 , 23, 633-40	17
2209	Evidence-based medicine in hypertension: what type of evidence?. 2005 , 23, 1113-20	42
2208	Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?. 2005 , 20, 250-5	10
2207	Managing the patient at risk for a second stroke. 2005 , 23, S41-7	6
2206	Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. 2005 , 23, 2113-8	37
2205	Beneficial effect of candesartan on rat diastolic heart failure. 2005 , 98, 372-9	15
2204	Diastolic Heart Failure and Critical Illness. 2005 , 197-211	1

2203	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. 2005 , 4, 469-475	
2202	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. 2005 , 4, 583-589	
2201	ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. 2005 , 23, 393-400	38
2200	Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. 2005 , 28, 307-14	70
2199	An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. 2005 , 28, 415-23	25
2198	Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. 2005 , 68, 1419-26	9
2197	Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. 2005 , 68, 2787-93	43
2196	A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. 2005 , 59, 571-8	12
2195	Management of diastolic heart failure--a practical review of pathophysiology and treatment trial data. 2005 , 59, 1239-46	11
2194	Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. 2005 , 19, 331-9	41
2193	Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. 2005 , 19, 923-31	43
2192	Chronic heart failure. 2005 , 17, 99-101	1
2191	Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure. 2005 , 96, 705-9	32
2190	Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. 2005 , 96, 867-71	39
2189	Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. 2005 , 96, 1530-6	86
2188	The emerging role of echocardiography in the screening of patients at risk of heart failure. 2005 , 96, 42L-51L	48
2187	Neurohumoral pathways in heart failure with preserved systolic function. 2005 , 47, 357-66	58
2186	Clinical trials in diastolic heart failure. 2005 , 47, 389-95	12

2185	Diastolic heart failure: definitions and terminology. 2005 , 47, 307-13	56
2184	Prognosis in diastolic heart failure. 2005 , 47, 333-9	26
2183	Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. 2005 , 25, 1213-29	72
2182	Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen. 2005 , 30, 356-67	32
2181	[Guidelines for therapy of chronic heart failure]. 2005 , 94, 488-509	56
2180	The ONTARGET/TRANSCEND Trial Programme: baseline data. 2005 , 42 Suppl 1, S50-6	35
2179	Heart Failure with Preserved Systolic Function. 2005 , 7, 55-59	2
2178	Treatment of heart failure with a normal ejection fraction. 2005 , 7, 317-25	2
2177	Issues with care in the elderly patient presenting with acute ischemia. 2005 , 7, 270-5	0
2176	Heart failure in women. 2005 , 7, 159-65	2
2175	Diastolic dysfunction and diastolic heart failure: mechanisms and epidemiology. 2005 , 7, 178-83	25
2174	Management of heart failure with pulmonary hypertension. 2005 , 7, 196-203	1
2173	Insulin resistance and the endothelium. 2005 , 5, 246-53	23
2172	Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?. 2005 , 2, 89-93	2
2171	Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. 2005 , 7, 240-3	24
2170	Angiotensin II-receptor antagonist in the treatment of hypertension. 2005 , 7, 287-93	6
2169	Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. 2005 , 269, 137-42	11
2168	Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials. 2005 , 24, 3805-21	23

2167	Angiotensin II Receptor Antagonists. 2005 , 705-724	1
2166	Chronic heart failure: developments and perspectives. 2005 , 20, 751-65	4
2165	ACE Inhibitors for Older Patients with Heart Failure: A Review of Evidence, Practice Patterns and Challenges. 2005 , 5, 89-99	
2164	EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE. 2005 , 1, 49-69	0
2163	Inhibition of the Renin-Angiotensin System and Atrial Fibrillation in Heart Failure. 2005 , 5, 214-219	1
2162	. 2005 ,	1
2161	The future of angiotensin II inhibition in cardiovascular medicine. 2005 , 5, 15-30	17
2160	Cardiovascular Disease in the Elderly. 2005 ,	
2159	Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome. 2005 , 7, 815-9	16
2158	The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. 2005 , 7, 542-51	19
2157	The diagnosis and management of chronic heart failure in the older patient. 2005 , 75-76, 49-62	11
2156	Drug treatment of systolic and of diastolic heart failure in elderly persons. 2005 , 60, 1597-605	7
2155	Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 2005 , 7, 650-6	20
2154	Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. 2005 , 112, 3738-44	540
2153	Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. 2005 , 112, 48-53	185
2152	Cardiomyocyte stiffness in diastolic heart failure. 2005 , 111, 774-81	395
2151	Diastolic heart failure: a review and primary care perspective. 2005 , 18, 189-98	18
2150	Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 2005 , 112, 3391-9	93

2149	Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. 2005 , 91, 489-94	59
2148	Heart failure with a normal ejection fraction. 2007 , 93, 155-8	156
2147	Ventricular arterial stiffening: integrating the pathophysiology. 2005 , 46, 185-93	282
2146	Acutely decompensated congestive heart failure: new therapies for an old problem. 2005 , 3, 925-36	
2145	Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. 2005 , 7, J5-J9	30
2144	[Diastolic heart failure -- therapy]. 2005 , 130, 1213-6; quiz 1217-20	4
2143	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the AdultâSummary Article. 2005 , 112, 1825-1852	334
2142	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). 2005 , 26, 215-25	1076
2141	Valsartan in chronic heart failure. 2005 , 39, 460-9	6
2140	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. 2005 , 26, 1115-40	1642
2139	Major clinical trials of hypertension: what should be done next?. 2005 , 46, 1-6	92
2138	Role of echocardiography in the contemporary management of chronic heart failure. 2005 , 3, 51-70	4
2137	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. 2005 , 10, 729-45	7
2136	Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. 2005 , 112, 300-3	23
2135	Joint National Committee VII and European Society of Hypertension/European Society of Cardiology guidelines for evaluating and treating hypertension: a two-way road?. 2005 , 16 Suppl 1, S74-7	20
2134	Pharmacotherapy of congestive heart failure in elderly patients. 2005 , 10, 85-94	5
2133	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 2006 , 27, 1447-58	29
2132	Angiotensin receptor blockers and risk of myocardial infarction: systematic review. 2005 , 331, 873	53

2131	Making sense of SENIORS. 2005 , 26, 203-6		23
2130	The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. 2005 , 26, 2251-8		36
2129	Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. 2005 , 26, 2706-13		143
2128	Review of the new ESC guidelines for the pharmacological management of chronic heart failure. 2005 , 7, J15-J20		1
2127	The role of angiotensin II receptor blockers in the management of heart failure. 2005 , 7, J10-J14		1
2126	Endothelial inflammation in insulin resistance. <i>Lancet, The</i> , 2005 , 365, 610-2	40	143
2125	Heart failure. <i>Lancet, The</i> , 2005 , 365, 1877-89	40	626
2124	Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. <i>Lancet, The</i> , 2005 , 366, 2005-11	40	327
2123	Indicaciones y uso clínico de los antagonistas de los receptores de la angiotensina II en la insuficiencia cardíaca. 2005 , 12, 103-112		
2122	Diastolic dysfunction in the older heart. 2005 , 19, 228-36		32
2121	[2005 Spanish guidelines in diagnosis and treatment of arterial hypertension]. 2005 , 125, 24-34		50
2120	[ARB II in chronic heart failure. Coincidences and divergences. Class effect?]. 2005 , 205, 499-506		
2119	Role of neurohormonal modulators in heart failure with relatively preserved systolic function. 2005 , 1, 77-93		3
2118	Therapeutic controversies in hypertension. 2005 , 25, 227-35		6
2117	The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. 2005 , 23, 165-83		22
2116	Management of cardiovascular disease in the renal transplant recipient. 2005 , 23, 331-42		7
2115	Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or both in chronic heart failure. 2005 , 1, 39-47		
2114	Diagnosis and management of heart failure in the outpatient setting. 2005 , 32, 1115-29, ix		10

2113	CHARMed - the effects of candesartan in heart failure. 2005 , 6, 513-6	2
2112	Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. 2005 , 39, 470-80	34
2111	The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. 2005 , 28, 2261-6	174
2110	Chronic heart failure: an overview of conventional treatment versus novel approaches. 2005 , 2, 628-38	30
2109	Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. 2005 , 5, 171-83	36
2108	Treating Hypertension with Angiotensin II Receptor Blockers. 2005 , 12, 9-15	2
2107	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation; endorsed by the Heart Rhythm Society. 2005 , 112, e154-235	1915
2106	Role of angiotensin II in the evolution of diastolic heart failure. 2005 , 7, 740-7	24
2105	Change in filling pattern with preload reduction reflects left ventricular relaxation. 2005 , 98, 67-72	3
2104	Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients. 2005 , 66, 630-42	2
2103	[Prevalence and management of heart failure in France: national study among general practitioners of the Sentinelles network]. 2005 , 26, 845-50	18
2102	The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 2005 , 149, 939-43	23
2101	Predictive power of ejection fraction and renal failure in patients admitted for chest pain without ST elevation in the troponin era. 2005 , 150, 666-73	7
2100	Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. 2005 , 150, 701-6	44
2099	Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). 2005 , 150, 464-70	14
2098	Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. 2005 , 18, 287-94	40
2097	Mechanisms for the clinical benefits of angiotensin II receptor blockers. 2005 , 18, 720-30	88
2096	The association of heart failure with insulin resistance and the development of type 2 diabetes. 2005 , 18, 731-7	63

2095	Renin-angiotensin system modulation: the weight of evidence. 2005 , 18, 127S-133S	19
2094	Office management of heart failure in the elderly. 2005 , 118, 342-8	36
2093	Update on the drug treatment of hypertension in patients with cardiovascular disease. 2005 , 118, 695-705	21
2092	[Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. 2005 , 58, 1062-92	57
2091	[Cardiac protection as priority strategy of cardiovascular prevention in high blood pressure]. 2005 , 205, 433-8	0
2090	Hypertensive heart disease. 2005 , 28, 191-202	97
2089	Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. 2005 , 28, 385-407	209
2088	Candesartan cilexetil: a review of its use in the management of chronic heart failure. 2005 , 65, 537-58	13
2087	Angiotensin antagonism in coronary artery disease: results after coronary revascularisation. 2005 , 65, 1073-96	11
2086	Candesartan treatment for peripheral occlusive arterial disease after stent angioplasty : a randomised, placebo-controlled trial. 2005 , 25, 89-97	2
2085	Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). 2005 , 11, 542-7	33
2084	The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. 2005 , 11, 576-85	113
2083	Surgical Treatment for Congestive Heart Failure—Towards Innovation. 2005 , 11, S255-S256	
2082	Application of Left Ventricular Assists Systems and Heart Transplantation as an Option for Profound Heart Failure Patients. 2005 , 11, S256	
2081	Diastolic Heart Failure: Diagnosis and Management. 2005 , 11, S256	
2080	Key issues in end point selection for heart failure trials: composite end points. 2005 , 11, 567-75	93
2079	Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. 2005 , 45, 661-7	110
2078	ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). 2005 , 46, e1-82	1119

2077	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. 2005 , 46, 1116-1143	314
2076	Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations. 2005 , 22, 913-41	27
2075	Diastolic heart failure in the elderly and the potential role of aldosterone antagonists. 2006 , 23, 299-308	16
2074	The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. 2006 , 23, 131-55	28
2073	Diastolic heart failure—a common and lethal condition by any name. 2006 , 355, 308-10	67
2072	Anaesthesia, Pain, Intensive Care and Emergency A.P.I.C.E.. 2006 ,	1
2071	Insuffisance cardiaque diastolique. 2006 , 2006, 23-27	
2070	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 28, 1462-536	1418
2069	The rationale and indications for angiotensin receptor blockers in heart failure. 2006 , 2, 81-8	2
2068	Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension. 2006 , 24, 1249-72	2
2067	Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications. 2006 , 6, 219-30	26
2066	Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. 2006 , 6, 373-81	18
2065	Candesartan for the management of heart failure: more than an alternative. 2006 , 7, 1945-56	3
2064	Angiotensin II antagonists—therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. 2006 , 22, 1-16	21
2063	Outcome of heart failure with preserved ejection fraction in a population-based study. 2006 , 355, 260-9	1451
2062	Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. 2006 , 22, 23-45	323
2061	Aportaciones científicas más relevantes del XVI Congreso de la Sociedad Europea de Hipertensión. Madrid, 12-15 de junio de 2006. 2006 , 23, 253-259	
2060	ARA-II en la insuficiencia cardiaca con función sistólica normal. ¿Dónde estamos y adónde vamos?. 2006 , 6, 37C-42C	

2059	What is the role of angiotensin-receptor blockade in cardiovascular protection?. 2006 , 152, 859.e1-8	4
2058	Diabetic hypertension. 2006 , 2, 25-36	4
2057	Heart failure in older adults. 2006 , 90, 863-85, xi	30
2056	Usefulness of left ventricular ejection fraction in patients with overt heart failure. 2006 , 81, 1638-9; author reply 1639	1
2055	Aportaciones científicas más relevantes del XVI Congreso de la Sociedad Europea de Hipertensión. Madrid, 12-15 de junio de 2006. 2006 , 23, 253-259	
2054	Effect of antihypertensive agents on the development of type 2 diabetes mellitus. 2006 , 81, 796-806	47
2053	Treatment of systolic and diastolic heart failure in the elderly. 2006 , 7, 29-36	15
2052	ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. 2006 , 66, 1169-77	17
2051	[Role of angiotensin II receptor antagonists in the treatment of metabolic syndrome]. 2006 , 206, 284-8	0
2050	Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms. 2006 , 29, 1007-12	19
2049	Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. 2006 , 47, 76-84	735
2048	The year in heart failure. 2006 , 48, 2575-83	7
2047	Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. 2006 , 12, 128-33	33
2046	Evaluation and management of patients with heart failure and preserved left ventricular ejection fraction. 2006 , 12, e80-5	13
2045	Quality of life in patients with signs and symptoms of heart failure--does systolic function matter?. 2006 , 12, 677-83	15
2044	Current perspectives in diastolic dysfunction and diastolic heart failure. 2006 , 92, 712-8	122
2043	Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. 2006 , 152, 956-66	57
2042	Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). 2006 , 19, 927-36	35

2041	Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. 2006 , 151, 92-9	23
2040	Anemia in patients with heart failure and preserved systolic function. 2006 , 151, 457-62	74
2039	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. 2006 , 151, 985-91	218
2038	Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. 2006 , 152, 246-52	21
2037	Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. 2006 , 185, 549-57	100
2036	. 2006 ,	1
2035	Management of Diastolic Dysfunction. 250-265	
2034	Angiotensin Receptor Blockers in the Treatment of Heart Failure. 44-56	
2033	Proposed new score to rate the strength of evidence and its application to large-scale clinical trials of angiotensin-receptor blockers. 2006 , 70, 1155-8	2
2032	Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. 2006 , 70, 124-8	10
2031	Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. 2006 , 70, 995-1000	31
2030	Managing heart failure in the very old. 2006 , 2, 253-275	
2029	Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. 2006 , 3, 733-749	3
2028	Left Ventricular Systolic Performance, Function, and Contractility in Patients With Diastolic Heart Failure. 2006 , 2006, 348-349	
2027	Thfapeutique diurctique. 2006 , 1, 1-26	
2026	Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?. 2006 , 2, 293-316	
2025	Effects of selective angiotensin II and beta1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals. 2006 , 24, S89-93	7
2024	Angiotensin II receptor blockers in congestive heart failure. 2006 , 14, 26-34	11

2023	European Society of Hypertension Scientific Newsletter: update on hypertension management: prevention of type 2 diabetes mellitus with antihypertensive drugs. 2006 , 24, 2478-82	6
2022	Diastolic heart failure: a myth. 2006 , 21, 240-8	48
2021	Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. 2006 , 21, 268-72	17
2020	Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. 2006 , 24, 1097-104	60
2019	Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. 2006 , 14, 108-24	91
2018	Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. 2006 , 24, S3-7	9
2017	Perioperative management of chronic heart failure. 2006 , 103, 557-75	137
2016	Diuretics: a modern day treatment option?. 2006 , 11, 419-27	12
2015	Candesartan. 2004 , 22, 263-84	29
2014	Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. 2006 , 60, 993-1002	21
2013	The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. 2006 , 61, 502-12	16
2012	Japanese Society of Hypertension. 2006 , 29, S1-S105	29
2011	Prognosis of patients with left ventricular diastolic pressure abnormality: a long-term survival study in patients without coronary artery disease. 2006 , 29, 121-4	5
2010	Current drug management of chronic heart failure. 2006 , 17, 21-31	0
2009	Pharmacological treatment of chronic heart failure. 2006 , 11, 109-23	23
2008	The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). 2006 , 11, 141-6	25
2007	Heart failure overview. 2006 , 11, 193-7	1
2006	Efficacy of Angiotensin receptor blockers in cardiovascular disease. 2006 , 20, 295-308	20

- 2005 [Drug treatment of chronic heart failure]. **2006**, 95 Suppl 4, 36-54; quiz 55-6 19
- 2004 The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. **2006**, 62, 885-92 9
- 2003 Future pharmacologic agents for treatment of heart failure in children. **2006**, 27, 533-51 19
- 2002 Diagnostic and therapeutic algorithms in chronic heart failure. **2006**, 31, 877-90 1
- 2001 Goals and guidelines for treating hypertension in a patient with heart failure. **2006**, 8, 334-44 8
- 2000 The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. **2006**, 6, 8-16 13
- 1999 Issues with care in the elderly patient presenting with acute ischemia. **2006**, 3, 51-6 4
- 1998 Hypertension and heart failure: diagnosis and management. **2006**, 8, 185-90 5
- 1997 De oudere patiënt met hartfalen en de rol van bèablokkers bij de behandeling. **2006**, 37, 70-81
- 1996 Concepto y pronóstico de insuficiencia cardiaca con fracción de eyección normal. **2006**, 6, 9F-14F
- 1995 Tratamiento médico de la insuficiencia cardiaca por disfunción diastólica. **2006**, 6, 53F-58F 1
- 1994 Características farmacológicas de los ARA-II. ¿Son todos iguales?. **2006**, 6, 10C-24C 1
- 1993 ¿Se necesitan más fármacos para el tratamiento de la insuficiencia cardiaca? Diferencias entre los ensayos clínicos y la práctica clínica. **2006**, 6, 25C-28C 1
- 1992 ¿Cuñdeberñ ser el fármaco que se añdiera a un IECA y un bloqueador beta en la insuficiencia cardiaca por disfunción sistólica: un antagonista de la aldosterona o un ARA-II? Evidencias clínicas con ambos. **2006**, 6, 29C-36C
- 1991 Prevención de la diabetes mellitus en los pacientes con insuficiencia cardiaca. **2006**, 6, 50C-57C
- 1990 Papel de los ARA-II en el tratamiento de la insuficiencia cardiaca: ¿quñdicen las guñas de práctica clínica?. **2006**, 6, 58C-72C
- 1989 Mechanisms of diastolic dysfunction in heart failure. **2006**, 16, 273-9 95
- 1988 From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. **2006**, 48, 326-41 208

1987	Long-term safety of antihypertensive therapy. 2006 , 49, 16-25	24
1986	Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. 2006 , 26, 1297-306	19
1985	Inflammation and the etiology of type 2 diabetes. 2006 , 22, 4-10	160
1984	The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. 2006 , 7, 40-4	37
1983	Failing older hearts? Of myths and left-overs. 2006 , 67, 176-7	
1982	Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. 2006 , 27, 562-8	84
1981	Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial. 2006 , 27, 929-35	109
1980	Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. 2006 , 27, 2257-9	17
1979	Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease. 2006 , 1, 47-54	5
1978	Antihypertensive Differentialtherapie bei Herzerkrankungen. 2006 , 32, 144-147	
1977	Diastolische Herzinsuffizienz. 2006 , 2, 27-45	
1976	Congestive Heart Failure. 2006 , 79-104	
1975	Current and future uses of candesartan in the treatment of heart failure. 2006 , 2, 391-402	
1974	Therapeutic potential of angiotensin receptor blockers in hypertension. 2006 , 15, 625-35	5
1973	Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years: incidence and long-term survival. 2006 , 8, 23-30	49
1972	Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. 2006 , 8, 409-19	24
1971	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. 2006 , 114, 2871-91	93
1970	Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. 2006 , 114, 838-54	194

1969	From hypertension to heart failure -- are there better primary prevention strategies?. 2006 , 7, 64-73	29
1968	Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. 2006 , 113, 671-8	694
1967	The diagnosis and management of chronic heart failure in the older patient. 2006 , 16, 199	
1966	Myocardial structure and function differ in systolic and diastolic heart failure. 2006 , 113, 1966-73	469
1965	Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. 2006 , 1, 193-208	44
1964	Angiotensin receptor blockers do not increase risk of myocardial infarction. 2006 , 114, 855-60	49
1963	New molecular mechanism in diastolic heart failure. 2006 , 113, 1922-5	72
1962	Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure. 2006 , 40, 1607-17	11
1961	Variable impact of combining fatal and nonfatal end points in heart failure trials. 2006 , 114, 2298-303	29
1960	Systolic and nonsystolic heart failure: equally serious threats. 2006 , 296, 2259-60	2
1959	Treatment of Advanced Heart Disease. 2006 ,	1
1958	Advanced systolic and diastolic function: beyond the E- and A-wave. 2006 , 10, 63-5	0
1957	Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. 2006 , 114, 2138-47	470
1956	The Diabetic Kidney. 2006 ,	1
1955	Cardiology in Family Practice. 2006 ,	
1954	Understanding diastolic heart failure with preserved ejection fraction: choosing the right model. 2006 , 47, 830-2	6
1953	Contemporary use of digoxin in the management of cardiovascular disorders. 2006 , 113, 2556-64	143
1952	Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. 2006 , 114, 397-403	437

1951	Insuffisance cardiaque «diastolique» ou ^ fonction systolique prservè. 2006 , 71-88	
1950	Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. 2006 , 7, 3-14	148
1949	Data Monitoring in Clinical Trials. 2006 ,	37
1948	Uncertainty on the use of aldosterone antagonists for primary therapy for sudden cardiac death in the setting of implanted devices. 2007 , 115, 2983-9; discussion 2989	1
1947	Diastolic heart failure in anaesthesia and critical care. 2007 , 98, 707-21	139
1946	Candesartan: from left ventricular hypertrophy to heart failure, a global approach. 2007 , 5, 825-34	1
1945	Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. 2007 , 13, 1335-45	34
1944	Angiotensin II and the cardiac complications of diabetes mellitus. 2007 , 13, 2721-9	18
1943	Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. 2007 , 9, 83-91	138
1942	Systolic and diastolic heart failure: different phenotypes of the same disease?. 2007 , 9, 136-43	56
1941	Unstable single coronary artery. 2007 , 28, 1048	
1940	Heart failure: are we neglecting the silent majority?. 2007 , 28, 1047-8	1
1939	The underuse of digoxin in heart failure, and approaches to appropriate use. 2007 , 176, 641-3	16
1938	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. 2007 , 11, 191-205	21
1937	Prognosis in heart failure with a normal ejection fraction. 2007 , 357, 829-30	50
1936	Serial changes in systolic and diastolic echocardiographic indices as predictors of outcome in patients with decreased left ventricular ejection fraction. 2007 , 8, 369-74	1
1935	[Care of hypertensive patients seen by cardiologists: results of the Snapshot Hypertension Registry]. 2007 , 132, 2430-5	6
1934	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. 2007 , 5, 767-76	12

1933	Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. 2007 , 115, 2761-88	557
1932	Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. 2007 , 50, 657-62	40
1931	Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. 2007 , 115, 2976-82; discussion 2982	25
1930	Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. 2007 , 9, 510-7	38
1929	The CHARM program: study design leads to findings of clinical and public health importance. 2007 , 12, 124-6	
1928	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 25, 1105-87	3825
1927	Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. 2007 , 25, 951-8	325
1926	REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. 2007 , 50,	13
1925	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. 2007 , 116, 1482-7	400
1924	Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade. 2007 , 71, 524-9	45
1923	Reducing diabetes incidence through the inhibition of the renin-angiotensin system: a strategy for reducing cardiovascular mortality and morbidity?. 2007 , 8, 473-82	2
1922	Heart failure: a disease for the Internist. 2007 , 28 Suppl 1, S27-9	
1921	Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update. 2007 , 9, 876-82	8
1920	Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. 2007 , 153, 189-200	49
1919	Diastolic heart failure and continuous hemodynamic monitoring. 2007 , 153, 6-11	2
1918	Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 2007 , 154, 277.e1-8	106
1917	Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 2007 , 154, 647-654	43
1916	Ability of myoglobin to predict mortality in patients admitted for exclusion of myocardial infarction. 2007 , 25, 873-9	13

1915	Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. 2007 , 120, 1090.e1-8	10
1914	Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. 2007 , 29, 1803-24	129
1913	High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. 2007 , 13, 422-30	560
1912	Diastolic heart failure and left ventricular diastolic dysfunction: what we know, and what we don't know!. 2007 , 115, 284-92	27
1911	Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study. 2007 , 118, 363-9	8
1910	Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results). 2007 , 1, 286-94	11
1909	[Diuretic-based therapy]. 2007 , 3, 392-426	3
1908	Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. <i>Lancet, The</i> , 2007 , 369, 2079-87 ⁴⁰	269
1907	Beneficios adicionales del tratamiento con candesartán en la insuficiencia cardíaca. Programa CHARM. 2007 , 24, 34-42	
1906	Perspectivas futuras del tratamiento con antagonistas de los receptores de la angiotensina. 2007 , 24, 43-50	
1905	Congestive heart failure in the elderly diabetic. 2007 , 33 Suppl 1, S32-9	15
1904	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. 2007 , 23, 21-45	110
1903	Heart-failure-complicating acute myocardial infarction. 2007 , 23, 123-39	1
1902	Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 2007 , 3, 477-84	
1901	Treatment of heart failure with abnormal left ventricular systolic function in the elderly. 2007 , 3, 423-36	1
1900	Spotlight on the Pharmacoeconomics of Candesartan Cilexetil in Chronic Heart Failure and Hypertension. 2007 , 15, 57-63	0
1899	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 16, 135-232	247
1898	Drug treatment of chronic heart failure in the elderly. 2007 , 24, 991-1006	10

1897	Do ACE Inhibitors/Angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. 2007 , 24, 945-55	8
1896	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. 2007 , 28, 2539-50	1934
1895	Intensive session: New approaches to medical issues in long-term care. 2007 , 8, 421-33	18
1894	Diastolic heart failure in the elderly. 2007 , 3, 437-53	14
1893	Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. 2007 , 9, 280-6	55
1892	Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. 2007 , 23, 1693-705	16
1891	Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction sufficiently evidence based?. 2008 , 94, 426-8	37
1890	Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 2007 , 23, 141-53	1
1889	Treatment of heart failure with abnormal left ventricular systolic function in the elderly. 2007 , 23, 61-81	2
1888	Pulmonary hypertension in older adults. 2007 , 28, 717-33, vi	11
1887	Diastolic heart failure in the elderly. 2007 , 23, 83-106	17
1886	Clinical manifestations, diagnostic assessment, and etiology of heart failure in older adults. 2007 , 23, 11-30	12
1885	DEFEAT heart failure: clinical manifestations, diagnostic assessment, and etiology of geriatric heart failure. 2007 , 3, 389-402	10
1884	Traitement de l'insuffisance cardiaque à fraction d'éjection préservée: Hiérarchisation des interventions à mettre en œuvre. 2007 , 2007, 17-21	2
1883	Heart failure-complicating acute myocardial infarction. 2007 , 3, 465-75	2
1882	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. 2007 , 60, 968.e1-94	29
1881	[Multifactorial treatment of atherosclerosis]. 2007 , 129, 785-96	0
1880	Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials. 2007 , 27, 149-61	5

1879	Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. 2007 , 49, 687-94	216
1878	Diastolic and systolic asynchrony in patients with diastolic heart failure: a common but ignored condition. 2007 , 49, 97-105	148
1877	Understanding "diastolic heart failure": the tip of the iceberg. 2007 , 49, 695-7	29
1876	Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. 2007 , 50, 591-6	102
1875	Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. 2007 , 50, 768-77	776
1874	Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. 2007 , 50, 1959-66	129
1873	Systolic and diastolic heart failure: differences and similarities. 2007 , 13, 569-76	105
1872	Pharmacologic therapy of chronic heart failure. 2007 , 7, 235-48	20
1871	Chronic Heart Failure. 2007 ,	
1870	Hypertension in Patients with Concomitant Cardiac Disorders. 2007 , 753-759	
1869	Angiotensin Receptor Blockers. 2007 , 254-267	
1868	Hypertension and Diabetes Mellitus. 2007 , 406-417	2
1867	. 2007 ,	6
1866	References. 233-253	
1865	Selective AT1 receptor antagonism enhances sympathetically mediated vasoconstriction in man. 2007 , 81, 83-7	5
1864	Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. 2007 , 61, 2093-102	9
1863	Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. 2007 , 18, 1231-5	28
1862	Angiotensin II receptor blockers for the treatment of heart failure: a class effect?. 2007 , 27, 526-34	17

1861	New studies influencing treatment of heart failure: 2006 update. 2007 , 27, 3S-11S	5
1860	Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. 2007 , 99, 1263-8	31
1859	Right ventricular failure in patients with preserved ejection fraction and diastolic dysfunction: an underrecognized clinical entity. 2007 , 13, 164-9	23
1858	Diastolic heart failure: a separate disease or selection bias?. 2007 , 49, 275-83	34
1857	Contribution of systolic and diastolic abnormalities to heart failure with a normal and a reduced ejection fraction. 2007 , 49, 229-40	58
1856	Efectos pleiotrpicos de telmisartn en el paciente diabtico. 2007 , 7, 23A-30A	
1855	Treatment of heart failure with normal left ventricular ejection fraction. 2007 , 33, 223-30	2
1854	[Guideline satisfying therapy for chronic heart failure]. 2007 , 48, 929-37	0
1853	[Hypertension and cardiac failure]. 2007 , 48, 909-20	2
1852	Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. 2007 , 7, 208-17	12
1851	Heart failure and cardiac hypertrophy. 2007 , 9, 289-301	18
1850	Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure. 2008 , 13, 91-8	25
1849	Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. 2008 , 13, 367-75	76
1848	Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. 2008 , 13, 439-52	22
1847	Treatment of patients with heart failure and preserved ejection fraction. 2008 , 10, 516-28	4
1846	Heart failure in women: An equal opportunity player in the expanding epidemic of heart failure. 2008 , 2, 210-216	
1845	Heart failure in older adults. 2008 , 2, 390-397	
1844	Aktuelle konservative Therapie der chronischen Herzinsuffizienz. 2008 , 22, 184-196	

1843	Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients. 2008 , 2, 1300-12	23
1842	Systolic function as a predictor of mortality and quality of life in long-term survivors with heart failure. 2008 , 31, 119-24	12
1841	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). 2008 , 29, 2388-442	2298
1840	Diastolic heart failure: state of the science on best treatment practices. 2008 , 20, 506-14	2
1839	Heart failure is not a diagnosis. 2008 , 62, 526-8	2
1838	Renin-angiotensin system gene polymorphisms and diastolic heart failure. 2008 , 38, 789-97	23
1837	Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. 2008 , 101, 639-44	27
1836	Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (. 2008 , 101, 1151-6	105
1835	Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction . 2008 , 102, 79-83	19
1834	Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. 2008 , 102, 733-7	82
1833	Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. 2008 , 102, 1681-6	21
1832	Implicaciones clínicas del programa ONTARGET en pacientes con cardiopatía isquémica crónica. 2008 , 8, 63E-72E	
1831	Beneficial effects of Waon therapy on patients with chronic heart failure: results of a prospective multicenter study. 2008 , 52, 79-85	58
1830	Heart failure with normal left ventricular ejection fraction: what is the evidence?. 2008 , 18, 280-92	36
1829	Irbesartan: a review of its use in hypertension and diabetic nephropathy. 2008 , 68, 1543-69	18
1828	Diastolic heart failure: mechanisms and controversies. 2008 , 5, 375-86	90
1827	[Clinical characteristics and management of hypertense patients diagnosed of heart failure in primary health care in Spain. HICAP Study]. 2008 , 208, 124-9	2
1826	Insuficiencia cardíaca en consultas ambulatorias: comorbilidades y actuaciones diagnóstico-terapéuticas por diferentes especialistas. Estudio EPISERVE. 2008 , 61, 611-619	29

1825	[Evaluation and management of hypertension in Spain. A consensus guide]. 2008 , 131, 104-16	49
1824	[Heart failure with normal systolic function: relevance of a clinical problem]. 2008 , 131, 171-2	
1823	Heart Failure in Outpatients: Comorbidities and Management by Different Specialists. The EPISERVE Study. 2008 , 61, 611-619	2
1822	Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. 2008 , 51, 679-89	275
1821	Treatment of heart failure with preserved systolic function. 2008 , 101, 361-72	6
1820	Assessing diastolic function in heart failure: a necessity!. 2008 , 101, 299-300	1
1819	Irbesartan in patients with heart failure and preserved ejection fraction. 2008 , 359, 2456-67	1307
1818	Heart failure with preserved ejection fraction: treat now by treating comorbidities. 2008 , 300, 431-3	125
1817	Diastolic Heart Failure. 2008 ,	3
1816	Optimal treatment of hypertension with diastolic heart failure. 2008 , 4, 117-24	6
1815	Future Therapies in Diastolic Heart Failure. 2008 , 435-441	
1814	Management of heart failure: a brief review and selected update. 2008 , 26, 561-71	1
1813	Diastolic heart failure. 2008 , 37, 405-16	26
1812	Diastolic heart failure in the elderly: underlying mechanisms and clinical relevance. 2008 , 125, 197-202	24
1811	"Diastolic" heart failure, overlooked systolic dysfunction, altered ventriculo-arterial coupling or limitation of cardiac reserve?. 2008 , 128, 299-303	6
1810	[Heart failure with preserved ejection fraction]. 2008 , 37, 1121-31	1
1809	[Prescribing beta blockers in elderly patients with heart failure]. 2008 , 37, 1047-54	2
1808	Predictive power of systolic function and congestive heart failure in patients with patients admitted for chest pain without ST elevation in the troponin era. 2008 , 156, 329-35	5

1807	Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. 2008 , 156, 1184-90	39
1806	Angiotensin receptor blockers: current status and future prospects. 2008 , 121, 656-63	56
1805	Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. 2008 , 121, S8-15	23
1804	Clinical outcome of patients with heart failure and preserved left ventricular function. 2008 , 121, 997-1001	27
1803	[Heart failure with preserved ejection fraction]. 2008 , 29 Suppl 1, S6-7	2
1802	Heart failure and diabetes mellitus: epidemiology and management of an alarming association. 2008 , 14, 615-25	76
1801	Correlation Between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. 2008 , 14, 687-94	35
1800	Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. 2008 , 14, 816-23	37
1799	Consultation between specialists in Internal Medicine and Family Medicine improves management and prognosis of heart failure. 2008 , 19, 548-54	10
1798	Tratamiento de la insuficiencia cardíaca del anciano. 2008 , 12, 1-10	
1797	Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. 2008 , 2, 239-66	15
1796	Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica (2008). 2008 , 61, 1329.e1-1329.e70	18
1795	Angiotensin receptor blockers: novel role in high-risk patients. 2008 , 26, 507-26	6
1794	Evidence-based performance and quality improvement in the acute cardiac care setting. 2008 , 24, 201-29, x	8
1793	Role of neurohormonal modulators in heart failure with relatively preserved systolic function. 2008 , 26, 23-40, vi	8
1792	Outcomes of patients with stable heart failure undergoing elective noncardiac surgery. 2008 , 83, 280-8	54
1791	Ventricular-vascular interaction in heart failure. 2008 , 4, 23-36	223
1790	Gestione dell'insufficienza cardiaca delle persone anziane. 2008 , 10, 1-10	

1789	Traditional and novel approaches to management of heart failure: successes and failures. 2008 , 26, 59-72, vi	15
1788	Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. 2008 , 4, 425-38	7
1787	Energizing diastole. 2008 , 4, ix-xiii	5
1786	Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy. 2008 , 4, 87-97	36
1785	Treatment of hypertension in heart failure with preserved ejection fraction: role of the kidney. 2008 , 4, 479-503	
1784	Hyperkalemia risk and treatment of heart failure. 2008 , 4, 455-64	1
1783	Arterial Hypertension and Cardiac Damage. 2008 , 15, 141-170	9
1782	Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction. 2008 , 15, 245-53	1
1781	Diabetes Mellitus. 2008 , 333-342	
1780	Coronary Artery Disease. 2008 , 277-286	
1779	Pathophysiology of Diastolic Heart Failure: Relaxation and Stiffness. 2008 , 11-25	4
1778	Aldosterone blockade in patients with chronic heart failure. 2008 , 26, 15-21, v	7
1777	Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. 2008 , 168, 2415-21	55
1776	Arterial stiffness and arterial wave reflections are associated with systolic and diastolic function in patients with normal ejection fraction. 2008 , 21, 1194-202	143
1775	Treating diastolic heart failure. 2008 , 94, 971-2	8
1774	Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention. 2008 , 26, 106-12	14
1773	Do we understand why the heart fails?. 2008 , 29, 698-700	3
1772	Treatment of heart failure in the elderly: never say it's too late. 2009 , 30, 391-3	13

1771 Assessment of Diastolic Heart Failure. **2008**, 89-101

1770 Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. **2008**, 29, 339-47 289

1769 Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. **2008**, 10, 149-56 144

1768 Arterioventricular coupling and ventricular efficiency after antihypertensive therapy: a noninvasive prospective study. **2008**, 51, 275-81 24

1767 Do we need to adjudicate major clinical events?. **2008**, 5, 56-60 97

1766 The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. **2008**, 30, 397-414 4

1765 Prevention of macrovascular disease in type 2 diabetic patients: blockade of the renin-angiotensin-aldosterone system. **2008**, 4, 63-78 5

1764 Management of Heart Failure. **2008**, 1

1763 Independence of restrictive filling pattern and LV ejection fraction with mortality in heart failure: an individual patient meta-analysis. **2008**, 10, 786-92 61

1762 BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. **2008**, 10, 252-9 77

1761 Effect of atrial fibrillation on long-term survival in patients hospitalised for heart failure with preserved ejection fraction. **2008**, 10, 566-72 36

1760 Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. **2008**, 94, 1147-53 64

1759 The therapeutic role of RAS blockade in chronic heart failure. **2008**, 2, 167-77 30

1758 Aging and the brain renin-angiotensin system: relevance to age-related decline in cardiac function. **2008**, 4, 237-45 6

1757 The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. **2008**, 168, 1699-704 165

1756 Defined Daily Doses: Ein Instrument zur Kostensteuerung im Gesundheitswesen?. **2008**, 13, 38-42 1

1755 Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure: the roles of diastolic dysfunction and renal insufficiency. **2008**, 31, 1865-72 15

1754 Exaggerated hypertensive response to exercise in patients with diastolic heart failure. **2008**, 31, 679-84 17

1753	Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction. 2008 , 4, 37-46	13
1752	Sex differences in response to chronic heart failure therapies. 2008 , 6, 555-65	15
1751	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). 2008 , 10, 933-89	1355
1750	Prise en charge de l'insuffisance cardiaque des personnes âgées. 2008 , 3, 1-10	
1749	“All for one, one for all” Evaluating composite endpoints in clinical trials. 2008 , 141, 28-31	
1748	Health-related quality of life of outpatients with systolic and isolated diastolic dysfunction: Sado Heart Failure Study. 2008 , 72, 1436-42	8
1747	Inhibition of the renin-angiotensin system prevents re-hospitalization of heart failure patients with preserved ejection fraction. 2008 , 72, 2004-8	8
1746	A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006. 2008 , 4, 167-176	1
1745	Does body mass index really matter in the management of heart failure?: a review of the literature. 2008 , 16, 124-8	8
1744	Heart failure in the elderly. 2008 , 4, 137-155	1
1743	Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function—a preliminary report. 2008 , 63, 683-92	13
1742	Current understanding of heart failure with preserved ejection fraction. 2007 , 22, 578-85	3
1741	Development of heart failure in recent hypertension trials. 2008 , 26, 1477-86	80
1740	Impact of diabetes and hypertension on the heart. 2008 , 23, 340-9	28
1739	Acute heart failure with preserved systolic function. 2008 , 36, S52-6	20
1738	Advances in the treatment of heart failure with a preserved ejection fraction. 2008 , 23, 233-40	5
1737	Diagnosis Of Heart Failure With Preserved Ejection Fraction. 2008 , 4, 8-12	1
1736	Treatment of heart failure with preserved systolic function in the elderly. 2008 , 4, 157-170	

1735	Diastolic dysfunction: a link between hypertension and heart failure. 2008 , 44, 503-13	40
1734	Severe Heart Failure. 2008 , 559-587	
1733	Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. 2008 , Volume 4, 223-234	4
1732	Role of Neurohormones. 2008 , 345-366	
1731	Aging and Diastolic Heart Failure. 2008 , 385-401	1
1730	Ventricular-Arterial Interaction in Patients with Heart Failure and a Preserved Ejection Fraction. 2008 , 403-412	
1729	General Treatment of Diastolic Heart Failure. 2008 , 415-427	
1728	Echo-Based Approach to the Management of Diastolic Heart Failure. 2008 , 429-434	
1727	The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. 2009 , 5, 233-42	18
1726	Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. 2009 , 5, 1043-58	9
1725	Heart Failure. 125-138	
1724	Diagnosis and Management of Heart Disease in the Elderly. 102-122	
1723	TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS. 2009 , 5, 85-92	0
1722	Candesartan cilexetil in the treatment of chronic heart failure. 2009 , 5, 257-64	3
1721	Comparative assessment of angiotensin receptor blockers in different clinical settings. 2009 , 5, 939-48	13
1720	Therapeutic strategies for diastolic dysfunction: a clinical perspective. 2009 , 17, 86-95	14
1719	Current controversies in drug use. 2009 , 8, i15-i20	
1718	Angiotensin II receptor blockers in the prevention of atrial fibrillation. 2009 , 10, 1395-411	2

1717	High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population. 2009 , 69, 865-72	5
1716	Vascular and metabolic effects of angiotensin II receptor blockers. 2009 , 10, 173-89	12
1715	Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. 2009 , 6, 239-51	84
1714	The heart failure spectrum: time for a phenotype-oriented approach. 2009 , 119, 3044-6	31
1713	Blocking aldosterone in heart failure. 2009 , 3, 379-85	14
1712	Conivaptan: promise of treatment in heart failure. 2009 , 10, 2161-9	7
1711	The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. 2009 , 7, 9-16	6
1710	Contemporary management of hypertension--how to optimize therapy. 2009 , 9, 181-92	1
1709	2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. 2009 , 119, e381-479	1178
1708	ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. 2009 , 119, 2250-94	829
1707	Identifying needs and opportunities for advancing translational research in cardiovascular disease. 2009 , 83, 425-35	20
1706	Office management of patients with diastolic heart failure. 2009 , 180, 520-7	5
1705	Irbesartan for heart failure with preserved ejection fraction. 2009 , 360, 1256-7; author reply 1258-9	
1704	Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography. 2009 , 32, 895-900	16
1703	Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat. 2009 , 3, 245-57	7
1702	Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. 2009 , 297, H375-86	22
1701	Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. 2009 , 11, 68-76	78
1700	A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. 2009 , 11, 980-9	29

1699	Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. 2009 , 11, 198-204	39
1698	Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. 2009 , 20, 2246-52	14
1697	Heart Failure with Preserved Ejection Fraction. 2009 , 59-71	
1696	Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. 2009 , 2, 129-37	92
1695	Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. 2009 , 32, 915-20	49
1694	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. 2009 , 11, 170-7	247
1693	Understanding heart failure with preserved ejection fraction: clinical importance and future outlook. 2009 , 15, 186-92	5
1692	Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. 2009 , 12, 43-50	10
1691	Analysis of recent papers in hypertension, Jan Basile, MD, Senior Editor. 2009 , 11, 102-5	1
1690	Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. 2009 , 15, 68-74	25
1689	Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. 2009 , 103, 829-33	38
1688	Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus . 2009 , 103, 845-51	59
1687	Death and dying in heart failure with normal ejection fraction. 2009 , 104, 1311-4	4
1686	Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. 2009 , 104, 1413-5	23
1685	Diastolic heart failure: a misNOMer. 2009 , 104, 465-7	17
1684	Treatment of heart failure with preserved ejection fraction. 2009 , 11, 79-87	7
1683	Update on Renin-Angiotensin-aldosterone blockade in heart failure. 2009 , 11, 455-66	1
1682	Evolving insights into the pathophysiology of heart failure with preserved ejection fraction. 2009 , 3, 374-379	1

1681	Irbesartan in patients with heart failure and preserved ejection fraction. 2009 , 3, 311-312	6
1680	Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008. 2009 , 3, 16-23	7
1679	Hypertension and diastolic heart failure. 2009 , 11, 422-9	27
1678	Treatment of hypertension in metabolic syndrome: implications of recent clinical trials. 2009 , 9, 229-37	5
1677	Heart failure with normal ejection fraction: consideration of mechanisms other than diastolic dysfunction. 2009 , 6, 57-64	33
1676	Does angiotensin receptor blockade improve outcomes in patients with heart failure and preserved ejection fraction? Results of the I-PRESERVE study. 2009 , 6, 65-67	
1675	Hyperkalemia in patients with heart failure: incidence, prevalence, and management. 2009 , 6, 272-80	39
1674	Therapeutic approaches to diastolic dysfunction. 2009 , 11, 283-91	12
1673	Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment. 2009 , 34, 89-96	20
1672	Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. 2009 , 24, 294-300	10
1671	Prescribing trends and drug budget impact of the ARBs in the UK. 2009 , 12, 302-8	8
1670	Evidence-based drug treatment of chronic heart failure. 2009 , 20, 22-36	
1669	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. 2009 , 7, 735-48	32
1668	Target-organ protection with combination renin-angiotensin-system blockade. 2009 , 32, 4-12	4
1667	Prolonged electrocardiogram QRS duration independently predicts long-term mortality in patients hospitalized for heart failure with preserved systolic function. 2009 , 15, 553-60	13
1666	Heart failure with a normal ejection fraction (HFNEF): embracing complexity. 2009 , 15, 561-4	9
1665	A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. 2009 , 15, 727-35	31
1664	Clinical features and prognosis of heart failure in women. A 5-year prospective study. 2009 , 133, 327-35	11

1663	[Current role of angiotensin II receptor antagonists and their combination in the treatment of hypertension]. 2009 , 132, 792-6	
1662	Heart failure with preserved ejection fraction in older adults. 2009 , 122, 713-23	19
1661	A review of heart failure management in the elderly population. 2009 , 7, 233-49	47
1660	Heart failure guidelines and implications for surgically treating heart failure. 2009 , 90, 874-88; quiz 889-92	2
1659	Increasing post-myocardial infarction heart failure incidence in elderly patients a call for action. 2009 , 53, 21-3	12
1658	Heart failure with normal left ventricular ejection fraction. 2009 , 53, 905-18	197
1657	ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. 2009 , 53, 1573-619	1257
1656	The role of the pulmonary vasculature in heart failure with preserved ejection fraction. 2009 , 53, 1127-9	7
1655	Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). 2009 , 53, 2150-8	311
1654	N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. 2009 , 55, 53-60	259
1653	Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. 2009 , 54, 1674-82	100
1652	Insuficiencia cardíaca con fracción de eyección preservada: principios del manejo. 2009 , 209, 23-29	
1651	Novedades terapéuticas: estudio I-PRESERVE. 2009 , 209, 36-40	
1650	Hypertension and heart failure: a dysfunction of systole, diastole or both?. 2009 , 23, 295-306	36
1649	Clinical update on nursing home medicine: 2009. 2009 , 10, 530-53	9
1648	Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. 2009 , 9, 29-43	14
1647	On target to dual block RAS?. 2009 , 60, 739-49	1
1646	A propensity score-based case-control study of renin-angiotensin system gene polymorphisms and diastolic heart failure. 2009 , 205, 497-502	30

1645	Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy. 2009 , 3, 52-68		3
1644	Heart failure. <i>Lancet, The</i> , 2009 , 373, 941-55	40	131
1643	Tratamiento de la insuficiencia cardiaca crónica. 2009 , 10, 2340-2348		
1642	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. 2009 , 53, e1-e90		1224
1641	Diastolic dysfunction as a link between hypertension and heart failure. 2009 , 93, 647-64		39
1640	Prevalenza, caratteristiche e trattamento dello scompenso cardiaco diastolico in una coorte di pazienti ospedalizzati: lo studio PRESYP-HF Toscana. 2009 , 3, 154-162		
1639	Hypertension and cardiac failure in its various forms. 2009 , 93, 665-80		23
1638	Observation unit management of acute decompensated heart failure. 2009 , 5, 85-100, vii		8
1637	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. 2009 , 27, 941-6		27
1636	The challenges associated with current clinical trials for diastolic heart failure. 2009 , 24, 230-8		7
1635	Perioperative optimization of the heart failure patient. 2009 , 47, 121-35		1
1634	Mortality in diastolic heart failure: an update. 2009 , 17, 51-5		11
1633	Management of left ventricular diastolic heart failure: is it only blood pressure control?. 2009 , 24, 161-6		7
1632	1. New Developments of Pathophysiology, Diagnosis and Treatment of Chronic Heart Failure. 2009 , 98, 2086-2100		
1631	3) Heart Failure. 2009 , 98, 2188-2193		
1630	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. 2009 , 2009, 364-367		
1629	Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. 2009 , 116, 467-77		106
1628	Pharmacological Treatment. 2009 , 79-96		

1627	Elevated E/E' predicts prognosis in congestive heart failure patients with preserved systolic function. 2009 , 73, 86-91	43
1626	Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction. 2009 , 73, 92-9	33
1625	Heart failure with preserved ejection fraction. 2009 , 73, 404-10	46
1624	Incremental prognostic value of stress/rest gated perfusion SPECT in patients with coronary artery disease--subanalysis of the J-ACCESS study. 2009 , 73, 2288-93	21
1623	Statin therapy in patients with heart failure and preserved left ventricular function. 2009 , 73, 1359; author reply 1360	1
1622	Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). 2009 , 73, 1893-900	236
1621	[How to evaluate and treat heart failure with preserved left ventricular ejection fraction]. 2009 , 64, 101-9	
1620	References. 2009 , 32, 91-107	
1619	Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. 2009 , 27, 502-7	53
1618	Outcome of heart failure with preserved ejection fraction: a multicentre spanish registry. 2009 , 5, 334-42	6
1617	Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure. 2009 , 10, 206-19	13
1616	Irbesartan and hydrochlorothiazide association in the treatment of hypertension. 2009 , 7, 120-36	2
1615	Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. 2010 , 28, 1356-65	59
1614	2. Current Status and Future Prospects of Diagnosis Using Echocardiography.. 2010 , 99, 554-558	
1613	Echocardiographic evaluation of diastolic heart failure. 2010 , 13, 14-26	3
1612	Heart failure in the elderly: diastolic heart failure, medical therapy, women and end-of-life care. 2010 , 6, 429-437	
1611	Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β blockers. 2010 , 74, 2346-52	10
1610	Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors. 2010 , 113, 224-33	16

1609	Heart Failure with a Normal Ejection Fraction. 2010 , 123-137	
1608	Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. 2010 , 10, 46-53	34
1607	[Treatment of progressive heart failure: pharmacotherapy, resynchronization (CRT), surgery]. 2010 , 35, 94-101	2
1606	Association of glucose metabolism with diastolic function along the diabetic continuum. 2010 , 53, 1331-40	102
1605	Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. 2010 , 99, 75-82	14
1604	Comparing angiotensin II receptor blockers on benefits beyond blood pressure. 2010 , 27, 257-84	16
1603	Diastology 2010: clinical approach to diastolic heart failure. 2010 , 8, 65-79	12
1602	Evolving approaches to the management of heart failure with preserved ejection fraction in patients with coronary artery disease. 2010 , 12, 58-75	24
1601	Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. 2010 , 24, 679-86	36
1600	Fahreignung bei kardiovaskulären Erkrankungen. 2010 , 4, 441-473	20
1599	Does irbesartan improve the risk of death or hospitalization for cardiovascular causes among patients with HF and PEF?. 2010 , 12, 193-5	2
1598	Myocardial ischemia in patients with diastolic dysfunction and heart failure. 2010 , 12, 216-22	20
1597	Heart failure is preventable. 2010 , 7, 91-2	
1596	Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. 2010 , 5, 469-79	12
1595	Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. 2010 , 24, 33-40	1
1594	Irbesartán no reduce la mortalidad global ni la morbilidad cardiovascular en pacientes con insuficiencia cardíaca y fracción de eyección preservada. 2010 , 17, 190	
1593	Clinical characteristics and outcomes of heart failure with preserved ejection fraction: lessons from epidemiological studies. 2010 , 55, 13-22	39
1592	Factors associated with increased hospital utilization in patients with heart failure and preserved ejection fraction. 2010 , 30, 646-53	6

1591	Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study). 2010 , 105, 223-8	9
1590	Noninvasive prediction of left ventricular systolic dysfunction in patients with clinically suspected heart failure using acoustic cardiography. 2010 , 16, 249-53	11
1589	Hypertension as an underlying factor in heart failure with preserved ejection fraction. 2010 , 12, 277-83	15
1588	Recognising and Managing the Patient with Heart Failure and Preserved Ejection Fraction. 2010 , 255-286	
1587	Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. 2010 , 83-116	
1586	Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. 2010 , 9, 63	61
1585	Pharmacotherapy of Chronic Heart Failure in the Elderly: A Review of the Evidence. 2010 , 2, CMT.S2794	
1584	Heart failure with preserved ejection fraction - coming to terms with an oxymoron. 2010 , 192, 4-5	61
1583	Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. 2010 , 3, 45-55	1
1582	The heart failure epidemic. 2010 , 7, 1807-30	68
1581	Cardio classics revisited--focus on the role of candesartan. 2010 , 6, 1047-63	2
1580	Treatment of heart failure with normal ejection fraction. 2010 , 94, 391-402, 414-26	
1579	Heart failure with normal ejection fraction. 2010 , 94, 652-60, 694-702	6
1578	Warfarin or not. 2010 , 40, 379; author reply 379-80	
1577	Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. 2010 , 121, 1393-405	241
1576	Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials. 2010 , 7, 69-77	17
1575	Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial. 2010 , 304, 1331-8	144
1574	Evolving focus on diastolic dysfunction in patients with coronary artery disease. 2010 , 25, 613-21	36

1573	Heart Failure in Clinical Practice. 2010 ,	4
1572	Evidence for the efficacy of ARBs across the cardiovascular continuum. 2010 , 26, 1203-18	12
1571	Is the effect of angiotensin receptor blockade in patients with heart failure modified by treatment with aspirin? The answer is not so clear!. 2010 , 12, 639-41	
1570	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. 2010 , 12, 738-45	9
1569	Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy. 2010 , 12, 581-7	81
1568	The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. 2010 , 12, 1309-16	89
1567	Candesartán en el tratamiento y prevención de la insuficiencia cardiaca crónica en España: impacto presupuestario como resultado de agregar candesartán a los tratamientos actuales. 2010 , 7, 26-37	
1566	Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. 2010 , 3, 659-67	256
1565	Heart Failure with Preserved Ejection Fraction. 2010 , 176-181	
1564	A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. 2010 , 3, 477-85	103
1563	Heart failure registry: a valuable tool for improving the management of patients with heart failure. 2010 , 12, 25-31	111
1562	HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials. 2010 , 12, 99-103	3
1561	Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. 2010 , 12, 181-5	24
1560	Arzneiverordnungs-Report 2010. 2010 ,	28
1559	Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. 2010 , 12, 294-300	36
1558	From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. 2010 , 117, 163-73	10
1557	Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial--an echocardiographic study. 2010 , 11, 165-71	59
1556	Current controversies in heart failure with a preserved ejection fraction. 2010 , 6, 97-111	18

1555	Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy. 2010 , 6, 743-7	3
1554	Heart failure in the elderly: advances and challenges. 2010 , 8, 695-715	20
1553	Clinical pearls in cardiology. 2010 , 85, 473-8	1
1552	Prevention, diagnosis, and treatment of hypertensive heart disease. 2010 , 28, 675-91	24
1551	Particularités de l'insuffisance cardiaque du sujet âgé et attitude thérapeutique. 2010 , 2010, 30-38	
1550	Treatment of heart failure with normal ejection fraction: an inconvenient truth!. 2010 , 55, 526-37	196
1549	Pre-clinical diastolic dysfunction in diabetic patients: where do we go from here?. 2010 , 55, 306-8	8
1548	Is rehospitalization after heart failure admission a marker of poor quality? Time for re-evaluation. 2010 , 56, 369-71	13
1547	Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. 2010 , 56, 855-63	248
1546	Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project. 2010 , 103, 404-10	9
1545	Diastolic heart failure in elderly: the prognostic factors and interventions regarding heart failure with preserved ejection fraction. 2010 , 138, 311-3	4
1544	Low-dose angiotensin receptor blockers as an alternative to ACE-inhibitors increase the risk of appropriate ICD interventions in heart failure. 2010 , 145, 522-4	1
1543	The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. 2010 , 16, 260-7	78
1542	Section 11: Evaluation and Management of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction. 2010 , 16, e126-e133	3
1541	Do heart failure trials need an end point committee?. 2010 , 160, 571-3	1
1540	Chronic Cardiac Failure. 2010 , 272-285	1
1539	Chronic heart failure: contemporary diagnosis and management. 2010 , 85, 180-95	139
1538	The evolution of angiotensin blockade in the management of cardiovascular disease. 2010 , 26 Suppl E, 7E-13E	8

1537	Renin Angiotensin System and Cardiovascular Disease. 2010 ,	2
1536	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2010 , 145-182	1
1535	Pharmacologic management of heart failure with preserved ejection fraction. 2010 , 44, 1933-45	14
1534	Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. 2010 , 341, c4130	27
1533	Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). 2010 , 12, 874-82	50
1532	The cardiovascular continuum refined: A hypothesis. 2010 , 19, 273-7	7
1531	Candesartan in the treatment of hypertension: what have we learnt in the last decade?. 2011 , 10, 957-68	5
1530	Diagnosis and management of left ventricular diastolic dysfunction in the hypertensive patient. 2011 , 24, 507-17	29
1529	CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. 2011 , 13, 929-36	57
1528	Chronic heart failure in older adults. 2011 , 95, 439-61, ix	10
1527	Coronary artery plaque burden does not affect left ventricular diastolic function in asymptomatic adults with normal ejection fraction. 2011 , 24, 909-14	13
1526	Ventricular-vascular interaction in heart failure. 2011 , 29, 447-59	93
1525	Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. 2011 , 57, 1676-86	112
1524	Abnormal calcium homeostasis: one mechanism in diastolic heart failure. 2011 , 58, 155-7	20
1523	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. 2011 , 57, 2037-114	325
1522	Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. 2011 , 58, 1780-91	406
1521	Heart Failure (Part 2). 2011 , 2, 237-244	
1520	Ethical considerations in geriatric cardiology. 2011 , 2, 363-370	1

1519	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. 2011 , 43, 60-8	425
1518	Chronic heart failure: current evidence, challenges to therapy, and future directions. 2011 , 11, 153-71	36
1517	Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. 2011 , 32, 670-9	715
1516	Traitement de l'insuffisance cardiaque du sujet âgé. 2011 , 11, 114-123	
1515	Hormonal Mechanisms of Cardiac Remodeling in Heart Failure. 2011 , 215-229	1
1514	Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?. 2011 , 86, 531-9	37
1513	Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. 2011 , 24, 651-62	101
1512	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. 2011 , 162, 900-6	93
1511	Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. 2011 , 162, 966-972.e10	188
1510	Acute heart failure: lessons learned so far. 2011 , 27, 284-95	9
1509	Diastolic heart failure: progress, treatment challenges, and prevention. 2011 , 27, 302-10	31
1508	Heart failure with recovered ejection fraction: a distinct clinical entity. 2011 , 17, 527-32	91
1507	The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction. 2011 , 17, 547-55	25
1506	Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). 2011 , 17, 634-42	138
1505	Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. 2011 , 22, 53-6	17
1504	Outcomes assessment in the SPRINT multicenter tibial fracture trial: Adjudication committee size has trivial effect on trial results. 2011 , 64, 1023-33	8
1503	Heart failure etiology impacts survival of patients with heart failure. 2011 , 149, 211-215	28
1502	Cardiovascular disease in the elderly. 2011 , 64, 697-712	45

1501	Prognosis for patients with heart failure with preserved ejection fraction. Is it the same as low ejection fraction?. 2011 , 64, 646-8	5
1500	Heart failure with preserved left ventricular ejection fraction: concepts, misconceptions and future directions. 2011 , 20, 129-33	3
1499	Heart failure with preserved ejection fraction: pathophysiology and emerging therapies. 2011 , 29, e6-21	26
1498	Republished technology and guidelines: the diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. 2011 , 87, 841-6	0
1497	The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. 2011 , 97, 411-6	25
1496	Cardiovascular Disease in the Elderly. 2011 , 64, 697-712	3
1495	Prognosis for Patients With Heart Failure With Preserved Ejection Fraction. Is It the Same As Low Ejection Fraction?. 2011 , 64, 646-648	
1494	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society	100
1493	Primary prevention of diastolic dysfunction in the normal heart: the "eyes wide shut" on a statin pleiotropic effect?. 2011 , 216, 272-4	5, 259-352
1492	Medical therapy for chronic heart failure. <i>Lancet, The</i> , 2011 , 378, 713-21	40 64
1491	Heart Failure as a Consequence of Hypertension. 2011 , 435-444	
1490	Heart failure with preserved ejection fraction: fighting misconceptions for a new approach. 2011 , 96, 504-14	19
1489	Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials. 2011 , 7, 391-7	4
1488	Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. 2011 , 2, 27-39	6
1487	Alterations in Ventricular Function. 2011 , 213-231	2
1486	A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. 2011 , 7, 297-313	15
1485	Heart Failure in Special Populations. 2011 , 716-727	
1484	The causes, consequences, and treatment of left or right heart failure. 2011 , 7, 237-54	24

1483	Key role of congestion in natural history of heart failure. 2011 , 4, 585-91	9
1482	Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). 2011 , 7, 85-95	7
1481	Differential clinical profile of candesartan compared to other angiotensin receptor blockers. 2011 , 7, 749-59	20
1480	Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. 2011 , 7, 605-22	21
1479	Treatment of Heart Failure with a Preserved Ejection Fraction. 2011 , 704-715	
1478	3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats. 2011 , 6, e22777	20
1477	Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. 2011 , 342, d2234	96
1476	Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -Comparison between preserved and reduced ejection fraction heart failure.-. 2011 , 75, 2605-13	107
1475	Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review. 2011 , 72, 369-80	5
1474	Protection against β adrenoceptor agonist reduction of plasma potassium in severe but not in moderate hypokalemia. 2011 , 25, 452-61	5
1473	Antifibrotic effects of ω fatty acids in the heart: one possible treatment for diastolic heart failure. 2011 , 21, 90-5	4
1472	Heart failure due to abnormal filling function of the heart. 2011 , 57, 148-59	9
1471	[Heart failure in the elderly patient]. 2011 , 211, 26-35	6
1470	Treatment of heart failure with preserved ejection fraction. 2011 , 31, 312-31	8
1469	Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction. 2011 , 107, 79-84	32
1468	Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia. 2011 , 107, 1644-9	9
1467	Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study). 2011 , 108, 1289-96	42
1466	A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age \geq 65 years. 2011 , 108, 1443-8	9

1465	Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. 2011 , 34, 426-32	41
1464	Usefulness of tissue Doppler imaging-myocardial performance index in the evaluation of diastolic dysfunction and heart failure with preserved ejection fraction. 2011 , 34, 494-9	29
1463	Irbesartan in patients with atrial fibrillation. 2011 , 364, 928-38	193
1462	An overview of candesartan in clinical practice. 2011 , 9, 975-82	6
1461	Baroreflex activation as a novel therapeutic strategy for diastolic heart failure. 2011 , 100, 249-51	19
1460	Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. 2011 , 100, 755-64	80
1459	The diabetic cardiomyopathy. 2011 , 48, 173-81	120
1458	Prognostic importance of comorbidities in heart failure with preserved left ventricular ejection fraction. 2011 , 26, 313-20	31
1457	[How should anesthesiologists perform ultrasound examinations? Diagnostic use of ultrasound in emergency and intensive care and medicine]. 2011 , 60, 203-13	5
1456	Treatment of heart failure with normal ejection fraction. 2011 , 13, 26-34	8
1455	Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. 2011 , 5, 440-449	75
1454	Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline. 2011 , 10, 15	5
1453	Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. 2011 , 4, 25	22
1452	NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. 2011 , 35, 715-20	19
1451	Future of personalized pharmacotherapy in chronic heart failure patients. 2011 , 7, 357-79	4
1450	Eblockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease. 2011 , 7, 43-53	2
1449	Mineralocorticoid receptor antagonists for heart failure. 2011 , 12, 2801-15	7
1448	Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. 2011 , 32, 2626-33	32

1447	Update on heart failure. 2011 , 11, 25-30	
1446	Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. 2011 , 13, 76-82	56
1445	Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. 2011 , 13, 1013-8	62
1444	Cardiovascular consequences of poor compliance to antihypertensive therapy. 2011 , 20, 196-203	10
1443	Candesartan cilexetil: an update. 2011 , 12, 1769-80	3
1442	Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients. 2011 , 53, 525-532	0
1441	Epidemiology and clinical course of heart failure with preserved ejection fraction. 2011 , 13, 18-28	442
1440	Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. 2011 , 13, 945-52	52
1439	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. 2011 , 123, 2434-506	255
1438	A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. 2011 , 4, 36-43	90
1437	CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. 2011 , 4, 651-8	51
1436	Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. 2011 , 123, 2006-13; discussion 2014	272
1435	Translational success stories: angiotensin receptor 1 antagonists in heart failure. 2011 , 109, 437-52	49
1434	Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function. 2011 , 16, 368-75	17
1433	Association of candesartan vs losartan with all-cause mortality in patients with heart failure. 2011 , 305, 175-82	46
1432	Metabolic remodelling in human heart failure. 2011 , 90, 251-7	58
1431	Effects of an angiotensin 2 receptor blocker plus diuretic combination drug in chronic heart failure complicated by hypertension. 2011 , 39, 1420-6	3
1430	Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. 2011 , 34, 62-9	34

1429	Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. 2011 , 34, 1179-84	18
1428	Combination inhibition of the renin-angiotensin system: is more better?. 2011 , 80, 245-55	13
1427	Insulin resistance and progression of heart failure in the older adult. 2011 , 7, 297-309	
1426	Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. 2011 , 301, H824-31	69
1425	Cardiorenal syndrome caused by heart failure with preserved ejection fraction. 2011 , 2011, 634903	22
1424	Chronic heart failure: we are fighting the battle, but are we winning the war?. 2012 , 2012, 279731	6
1423	Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension. 2012 , 2012, 124758	15
1422	Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. 2012 , 308, 2108-17	123
1421	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. 2012 , 33, 1787-847	3691
1420	Management strategies in atrial fibrillation in patients with heart failure. 2012 , 20, 288-96	3
1419	Nonsurgical therapy for heart failure. 2012 , 50, 1-21	
1418	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. 2012 , 5, 571-8	129
1417	Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. 2012 , 5, 720-6	174
1416	Community care in England: reducing socioeconomic inequalities in heart failure. 2012 , 126, 1050-7	36
1415	Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction. 2012 , 33, 1716-7	63
1414	Mortality in heart failure with preserved ejection fraction: an unacceptably high rate. 2012 , 33, 1718-20	28
1413	Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. 2012 , 14, 1179-88	38
1412	Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. 2012 , 14, 487-94	52

1411	Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. 2012 , 14, 219-25	123
1410	Heart failure highlights in 2011. 2012 , 14, 1090-6	2
1409	Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. 2012 , 13, 556-67	30
1408	Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF. 2012 , 35, 194-200	36
1407	Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. 2012 , 35, 93-9	18
1406	Pulmonary Hypertension and Left Heart Disease. 2012 , 161-168	
1405	Cardiology in Family Practice. 2012 ,	3
1404	Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study. 2012 , 17, 291-7	19
1403	The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease. 2012 , 13, 317-27	8
1402	Heart failure with preserved ejection fraction. 2012 , 2012, 10	11
1401	Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction: diagnosis and management. 2012 , 27, 281-7	9
1400	Heart failure therapy: what should clinicians believe?. 2012 , 308, 2144-6	5
1399	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. 2012 , 33, 1750-7	508
1398	Ca ²⁺ entry mode of Na ⁺ /Ca ²⁺ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. 2012 , 33, 1408-16	32
1397	Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. 2012 , 33, 1742-9	91
1396	Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?. 2012 , 105, 11-27	13
1395	Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. 2012 , 18, 4385-413	80
1394	Heart failure with preserved left ventricular function: diagnostic and therapeutic challenges in patients with diastolic heart failure. 2012 , 344, 399-405	4

1393	L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. 2012 , 30, 1834-44	42
1392	Disparities in heart failure and other cardiovascular diseases among women. 2012 , 8, 473-85	18
1391	Elderly women with heart failure: unseen, unheard or simply forgotten?. 2012 , 8, 191-204	2
1390	Treatment performance measures affect clinical outcomes in patients with acute systolic heart failure: report from the Korean Heart Failure Registry. 2012 , 76, 1151-8	45
1389	Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. 2012 , 76, 1662-9	59
1388	Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary hypertension). 2012 , 55, 104-18	14
1387	Management of Heart Failure. 2012 , 1, e161-e171	
1386	Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. 2012 , 23, 334-42	36
1385	Scope of heart failure hospitalization. 2012 , 18 Suppl 1, S1-4	4
1384	Treatment of isolated systolic hypertension in the elderly. 2012 , 10, 1367-73	14
1383	Diastolic heart failure: What we still don't know. Looking for new concepts, diagnostic approaches, and the role of comorbidities. 2012 , 37, 875-9	25
1382	Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor- β . 2012 , 30, e30-40	102
1381	What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. 2012 , 60, 2349-56	136
1380	Optimization of heart Failure medical Treatment after hospital discharge according to left ventricular Ejection fraction: the FUTURE survey. 2012 , 105, 355-65	38
1379	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 1387-95	40 756
1378	Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. 2012 , 16, 2958-67	8
1377	Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. 2012 , 37, 644-56	56
1376	Coexistence of obstructive sleep apnoea and metabolic syndrome is independently associated with left ventricular hypertrophy and diastolic dysfunction. 2012 , 16, 677-84	17

1375	Differences in Outcome of Heart Failure With Preserved or Depressed Systolic Function in Patients Older Than 70 Years Who Receive Beta Blockers. 2012 , 65, 22-28		
1374	Stage B heart failure: rationale for screening. 2012 , 8, 273-83		11
1373	Heart failure: can we define, assess, and treat diastolic heart failure?. 2012 , 14, 713-5		3
1372	The role of renin angiotensin system intervention in stage B heart failure. 2012 , 8, 225-36		3
1371	Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. 2012 , 43, 432-40		63
1370	Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. 2012 , 126, 65-75		53 ¹
1369	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. 2012 , 14, 803-69		189 ²
1368	Differences in outcome of heart failure with preserved or depressed systolic function in patients older than 70 years who receive beta blockers. 2012 , 65, 22-8		2
1367	[Heart failure with preserved ejection fraction: a systemic disorder?]. 2012 , 33, 370-80		5
1366	Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. 2012 , 163, 430-7, 437.e1-3		71
1365	Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. 2012 , 155, 249-56		31
1364	Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients. 2012 , 155, 236-42		26
1363	Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction--a meta analysis of 7 prospective clinical studies. 2012 , 155, 33-8		39
1362	Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. 2012 , 157, 108-13		41
1361	Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 2012 , 18, 265-81		42
1360	Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation. 2012 , 97, 185-94		32
1359	Effect of beta blocker therapy on survival of patients with heart failure and preserved systolic function following hospitalization with acute decompensated heart failure. 2012 , 23, 374-8		12
1358	Heart failure--does it matter whether LVEF is reduced?. <i>Lancet, The</i> , 2012 , 380, 1363-5	40	10

1357	Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. 2012 , 13, 2699-709	4
1356	The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review. 2012 , 19, 19-31	12
1355	Angiotensin receptor blockers for heart failure. 2012 , CD003040	39
1354	Invited editorial commentary for American Heart Journal mechanisms of exercise training in heart failure with preserved ejection fraction: central disappointment and peripheral promise. 2012 , 164, 807-9	6
1353	Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. 2012 , 59, 442-51	219
1352	Vasodilators across the heart failure spectrum not all patients, and not all vasodilators, are created equal. 2012 , 59, 452-4	1
1351	Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study. 2012 , 59, 673-80	94
1350	Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. 2012 , 59, 998-1005	455
1349	Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. 2012 , 59, 1785-95	119
1348	Sudden cardiac death in heart failure patients with preserved ejection fraction. 2012 , 18, 749-54	45
1347	Cardiovascular disease in women. 2012 , 37, 450-526	44
1346	Czech Society of Cardiology Guidelines for the Diagnosis and Treatment of Chronic Heart Failure 2011. 2012 , 54, e113-e134	9
1345	Treatment of diastolic dysfunction in hypertension. 2012 , 22, 613-8	17
1344	[Heart failure and development of type 2 diabetes mellitus]. 2012 , 138, 579-83	1
1343	Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function. 2012 , 79, 448-51	1
1342	Renal dysfunction in heart failure. 2012 , 96, 955-74	21
1341	Congestion is the driving force behind heart failure. 2012 , 9, 219-27	4
1340	Aging of the United States population: impact on heart failure. 2012 , 9, 369-74	79

- 1339 Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective. **2012**, 9, 363-8 26
- 1338 Le traitement du patient à insuffisance cardiaque : synthèse des données disponibles en 2012. **2012**, 4, 301-309
- 1337 Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. **2012**, 65, 938.e1-938.e59 27
- 1336 Manual of Outpatient Cardiology. **2012**,
- 1335 Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. **2012**, 12, 263-77 53
- 1334 Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. **2012**, 34, 86-91 9
- 1333 The Kidney in Heart Failure. **2012**,
- 1332 Managing the Kidney when the Heart is Failing. **2012**,
- 1331 New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. **2012**, 5, 19-25 9
- 1330 Angiotensin receptor blockers in preventing stroke: A systematic review and meta-analysis of randomized controlled trials. **2012**, 6, 3256-3264 1
- 1329 Heart failure with a normal ejection fraction: treatments for a complex syndrome?. **2012**, 14, 305-18 1
- 1328 Dissecting the "CHF admission": an evidence-based review of the evaluation and management of acute decompensated heart failure for the hospitalist. **2012**, 7, 439-45 2
- 1327 Heart failure with normal ejection fraction: a growing pandemic. **2012**, 8, 383-92 1
- 1326 Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management. **2012**, 17, 581-8 113
- 1325 New roles for renin and prorenin in heart failure and cardiorenal crosstalk. **2012**, 17, 191-201 52
- 1324 Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. **2012**, 17, 133-49 63
- 1323 Association of low plasma adiponectin with early diastolic dysfunction. **2012**, 18, 187-91 27
- 1322 Exercise training improves heart rate variability in older patients with heart failure: a randomized, controlled, single-blinded trial. **2012**, 18, 192-7 32

1321	Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia. 2012 , 24, 99-121	7
1320	Does achieving an intensive versus usual blood pressure level prevent stroke?. 2012 , 71, 133-40	30
1319	Heart failure with preserved ejection fraction: time for a new approach?. 2013 , 62, 272-4	20
1318	Tratamiento de la insuficiencia cardiaca crónica. 2013 , 11, 2146-2156	
1317	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. 2013 , 62, 1495-1539	233
1316	Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?. 2013 , 12, 108	7
1315	AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPAR α . 2013 , 12, 30	14
1314	Heart failure with normal ejection fraction: current diagnostic and management strategies. 2013 , 11, 1179-93	6
1313	Heart failure readmissions. 2013 , 15, 437-49	5
1312	Treating hypertension in patients with left ventricular dysfunction: hitting the fairway and avoiding the rough. 2013 , 10, 157-64	2
1311	Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. 2013 , 6, 501-15	58
1310	Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. 2013 , 18, 429-37	17
1309	Treatment for chronic heart failure in the elderly: current practice and problems. 2013 , 18, 529-51	63
1308	Congestive Heart Failure. 2013 , 255-302	
1307	Medication management of chronic heart failure in older adults. 2013 , 30, 765-82	15
1306	Heart Failure with Normal Left Ventricular Ejection Fraction: Basic Principles and Clinical Diagnostics. 2013 , 25-61	1
1305	A review of current therapies used in the treatment of congestive heart failure. 2013 , 11, 1171-8	8
1304	Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. 2013 , 169, 408-17	27

1303	Quantification of left ventricular performance in different heart failure phenotypes by comprehensive ergometry stress echocardiography. 2013 , 169, 311-5	5
1302	Heart failure therapy in patients with coronary artery disease. 2013 , 13, 205-9	10
1301	Iron deficiency in chronic heart failure: an international pooled analysis. 2013 , 165, 575-582.e3	355
1300	Heart failure with preserved ejection fraction: A moving target. 2013 , 32, 653-655	
1299	Traditional heart failure medications and sudden cardiac death prevention: a review. 2013 , 18, 412-26	19
1298	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2013 , 128, e240-327	1927
1297	Pathophysiology of diastolic dysfunction in chronic heart failure. 2013 , 9, 711-20	6
1296	Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. 2013 , 45, 37-50	48
1295	Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure. 2013 , 61, 267-74	1
1294	Heart failure: what does ejection fraction have to do with it?. 2013 , 62, 1-3	19
1293	Heart failure: a disease complex with challenging therapeutics. 2013 , 94, 415-21	5
1292	New therapeutic options in heart failure. What's on the horizon? An overview. 2013 , 170, 95-106	3
1291	Galectin-3 in heart failure with preserved ejection fraction. 2013 , 15, 1095-101	72
1290	Pharmacological treatment of acute heart failure: current treatment and new targets. 2013 , 94, 499-508	5
1289	Learning from recent trials and shaping the future of acute heart failure trials. 2013 , 166, 629-35	21
1288	RANoLazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. 2013 , 1, 115-22	123
1287	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). 2013 , 62, 1845-54	62
1286	Ventricular remodeling in heart failure with preserved ejection fraction. 2013 , 10, 341-9	37

1285	Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction. 2013 , 140, 156-66	11
1284	The economics of heart failure. 2013 , 9, 93-106	16
1283	Renin-angiotensin-aldosterone system inhibitors in heart failure. 2013 , 94, 459-67	38
1282	Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. 2013 , 126, 150-61	27
1281	Update on heart failure with preserved ejection fraction. 2013 , 7, 495-502	15
1280	N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). 2013 , 15, 1148-56	48
1279	Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). 2013 , 15, 110-8	210
1278	Frontiers of therapy for patients with heart failure. 2013 , 126, 6-12.e6	9
1277	Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel?. 2013 , 15, 5-8	10
1276	The past, present and future of renin-angiotensin aldosterone system inhibition. 2013 , 167, 1677-87	82
1275	Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. 2013 , 18, 761-95	35
1274	Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy. 2013 , 6, 254-63	41
1273	The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. 2013 , 29, 168-81	157
1272	[Diastolic heart failure: heart failure with preserved ejection fraction]. 2013 , 46, 71-9; quiz 80-1	2
1271	Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. 2013 , 166, 230-5	23
1270	Reply: To PMID 23500300. 2013 , 62, 567-8	
1269	Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. 2013 , 126, 401-10	30
1268	Angiotensin II receptor blockers for patients with chronic heart failure: the next step forward. 2013 , 61, 307-8	

1267	Strategies to prevent postdischarge adverse events among hospitalized patients with heart failure. 2013 , 9, 303-20, vi	10
1266	Epidemiology of hospitalized heart failure: differences and similarities between patients with reduced versus preserved ejection fraction. 2013 , 9, 271-6, v	11
1265	Myths and Facts About Heart Failure with Preserved Ejection Fraction: Risk Factors, Longevity, Potential Pharmacological and Exercise Interventions. 2013 , 7, 1-7	2
1264	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. 2013 , 112, 1158-64	62
1263	Examining the impact of clinical quality and clinical flexibility on cardiology unit performance—Does experiential quality act as a specialized complementary asset?. 2013 , 31, 505-522	38
1262	Diferencias y similitudes entre inhibidores de la enzima de conversi3n de la angiotensina y antagonistas de los receptores de la angiotensina II. 2013 , 30, 30-38	
1261	Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]). 2013 , 111, 1324-9	14
1260	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction. 2013 , 112, 1907-12	23
1259	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael). 2013 , 112, 1901-6	4
1258	[Heart failure with preserved ejection fraction: A moving target]. 2013 , 32, 653-5	0
1257	Recomenda3es de 2012 da ESC para o diagn3stico e o tratamento da insufici4ncia card3aca aguda e cr3nica. 2013 , 32, 641.e1-641.e61	
1256	Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial—rationale and design. 2013 , 62, 31-6	13
1255	Targeting the renin-angiotensin-aldosterone system in heart failure. 2013 , 10, 125-34	72
1254	Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. 2013 , 1, 40-7	36
1253	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 , 62, e147-239	4318
1252	B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. 2013 , 61, 1498-506	286
1251	No train, no gain: does this apply to heart failure with preserved ejection fraction?. 2013 , 162, 69-70	1
1250	RAAS inhibitors and cardiovascular protection in large scale trials. 2013 , 27, 171-9	66

1249	Integrating the myocardial matrix into heart failure recognition and management. 2013 , 113, 725-38	56
1248	Pharmacological management of chronic heart failure: old drugs, new drugs and new indications. 2013 , 74, C18-22	2
1247	Combination antihypertensive therapy among patients with COPD. 2013 , 143, 1312-1320	13
1246	[Pharmacologic treatment of heart failure in the elderly]. 2013 , 138, 700-2	
1245	Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. 2013 , 6, 184-92	122
1244	Angiotensin Receptor Blockers. 2013 , 191-203	
1243	Pulmonary hypertension associated with left heart disease. 2013 , 34, 665-80	11
1242	[Heart failure with preserved left ventricular ejection fraction]. 2013 , 102, 1299-307	2
1241	Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?. 2013 , 2013, 130724	11
1240	Diagnosing heart failure with preserved ejection fraction. 2013 , 7, 463-74	7
1239	Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats. 2013 , 20, 860-8	22
1238	Heart failure with a normal left ventricular ejection fraction: epidemiology, pathophysiology, diagnosis and management. 2013 , 346, 129-36	21
1237	Heart failure in the elderly. 2013 , 28, 234-41	8
1236	Atrial fibrillation and heart failure: beyond the heart rate. 2013 , 28, 332-6	3
1235	Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction. 2013 , 62, 485-90	15
1234	Heart failure with preserved ejection fraction: emerging drug strategies. 2013 , 62, 13-21	39
1233	Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. 2013 , 125, 110-7	32
1232	Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. 2013 , 309, 781-91	457

1231	Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction. 2013 , 18, 226-7	3
1230	Pharmacologic Management of Heart Failure in the Ambulatory Setting. 2013 , 241-269	1
1229	Pathological ventricular remodeling: mechanisms: part 1 of 2. 2013 , 128, 388-400	437
1228	Heart failure with preserved ejection fraction: current understanding and emerging concepts. 2013 , 28, 187-96	18
1227	TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?. 2013 , 2013, 357-60	1
1226	Similarities and Differences between the Pathogenesis and Pathophysiology of Diastolic and Systolic Heart Failure. 2013 , 2013, 824-135	21
1225	2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2013 , 128, 1810-52	2321
1224	How do patients with heart failure with preserved ejection fraction die?. 2013 , 15, 604-13	138
1223	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. 2013 , 15, 551-9	54
1222	Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. 2013 , 15, 1138-47	126
1221	Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan. 2013 , 15, 1194-202	14
1220	Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. 2013 , 77, 705-11	166
1219	Left ventricular stiffening as therapeutic target for heart failure with preserved ejection fraction. 2013 , 77, 886-92	19
1218	Guidelines for treatment of acute heart failure (JCS 2011). 2013 , 77, 2157-201	97
1217	Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function. 2013 , 345, 211-7	19
1216	Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). 2013 , 14, 332	4
1215	Heart failure with a preserved ejection fraction. 2013 , 74, C26-30	
1214	[Heart failure with preserved ejection fraction in sub-Saharan Africa: about 32 cases]. 2013 , 16, 100	1

1213 Heart Failure in Hypertension. **2013**, 262-269

1212 Effects of direct Renin inhibition on myocardial fibrosis and cardiac fibroblast function. **2013**, 8, e81612

23

1211 Heart Failure in Women: Epidemiology, Prognosis, and Management. **2013**, 1055-1068

1210 Prevalence, feature and treatment in a cohort of patients hospitalized for heart failure with preserved systolic function: data from the PRESYF-HF Toscana study. **2013**, 154-162

1209 Heart Failure with Preserved Ejection Fraction. **2014**, 185-191

0

1208 Heart failure in patients with chronic kidney disease: a systematic integrative review. **2014**, 2014, 937398

85

1207 Current Status of Heart Transplantation. **2014**, 403-423

1206 Carotid baroreceptor stimulation: a promising approach for the management of resistant hypertension and heart failure. **2014**, 12, 30-7

10

1205 Lessons Learned from the TOPCAT Trial. **2014**, 06,

1204 Heart failure with preserved ejection fraction. **2014**, 14 Suppl 6, s22-8

12

1203 Management of pulmonary hypertension due to heart failure with preserved ejection fraction. **2014**, 16, 501

3

1202 Epigenetic regulation and heart failure. **2014**, 12, 1087-98

7

1201 Effect of fluid and dietary sodium restriction in the management of patients with heart failure and preserved ejection fraction: study protocol for a randomized controlled trial. **2014**, 15, 347

4

1200 Chapter 6. Hypertension associated with organ damage. **2014**, 37, 301-314

1199 References. **2014**, 37, 362-387

37

1198 Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. **2014**, 35, 1041-50

72

1197 Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β in the rat heart. **2014**, 63, e60-7

57

1196 Herzinsuffizienz mit erhaltener LV-Funktion. **2014**, 10, 25-46

1195	Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. 2014 , 10, 693-8	9
1194	CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. 2014 , 7, 991-7	131
1193	Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. 2014 , 7, 104-15	174
1192	Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. 2014 , 16, 958-66	32
1191	Relationships between biomarkers and left ventricular filling pressures at rest and during exercise in patients after myocardial infarction. 2014 , 20, 959-67	12
1190	Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: rationale and design of a randomized controlled trial. 2014 , 168, 830-7.e1	10
1189	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. 2014 , 16, 33-40	141
1188	Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. 2014 , 16, 796-801	79
1187	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. 2014 , 16, 334-41	41
1186	The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). 2014 , 16, 1049-55	137
1185	Heart Failure with Preserved Ejection Fraction. 2014 , 193-203	
1184	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. 2014 , 7, 895-902	25
1183	Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists. 2014 , 21, 419-35	6
1182	Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. 2014 , 3, e001293	31
1181	Death by oxymoron? The enigma of heart failure with preserved ejection fraction. 2014 , 8, 1-3	2
1180	Comprehensive review of the prognostic value of galectin-3 in heart failure. 2014 , 22, 171-5	25
1179	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. 2014 , 7, 740-51	159
1178	Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?. 2014 , 2014, 652421	4

1177	Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. 2014 , 4, 669-78	14
1176	Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?. 2014 , 23, 449-55	4
1175	Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. 2014 , 173, 393-401	35
1174	Prognostic factors of heart failure with preserved ejection fraction: a 12-year prospective cohort follow-up study. 2014 , 171, 331-7	10
1173	"Fere libenter homines id quod volunt credunt": apprehension for the stroke reduction in the KYOTO HEART Study on the basis of meta-regression from the evidence. 2014 , 170, 258-60	
1172	Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. 2014 , 63, 853-71	80
1171	Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients. 2014 , 126, 195-200	16
1170	Spironolactone for heart failure with preserved ejection fraction. 2014 , 370, 1383-92	1365
1169	Pre-clinical diastolic dysfunction. 2014 , 63, 407-16	206
1168	Should there be sex-specific criteria for the diagnosis and treatment of heart failure?. 2014 , 7, 139-55	29
1167	Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure. 2014 , 11, 31-9	3
1166	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 2014 , 63, 1123-1133	1160
1165	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. 2014 , 2, 97-112	213
1164	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. 2014 , 16, 671-7	56
1163	Medical therapy in adults with congenital heart disease. 2014 , 10, 167-78	14
1162	The Right Heart. 2014 ,	1
1161	Hypertension as a risk factor for heart failure. 2014 , 16, 447	35
1160	Heart failure with preserved ejection fraction: a clinical dilemma. 2014 , 35, 1022-32	136

1159	The role of coronary artery disease in heart failure. 2014 , 10, 353-65	61
1158	Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. 2014 , 113, 691-6	39
1157	Heart failure with preserved ejection fraction: an ongoing enigma. 2014 , 32, 151-61, ix-x	9
1156	A novel approach to drug development in heart failure: towards personalized medicine. 2014 , 30, 288-95	14
1155	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization. 2014 , 30, 249-63	36
1154	Potential of resveratrol in the treatment of heart failure. 2014 , 95, 63-71	72
1153	Management of ACCF/AHA Stage C heart failure. 2014 , 32, 73-93, viii	7
1152	The renin-angiotensin-aldosterone system and heart failure. 2014 , 32, 21-32, vii	98
1151	Optimising exercise training in prevention and treatment of diastolic heart failure (OptimEx-CLIN): rationale and design of a prospective, randomised, controlled trial. 2014 , 21, 18-25	48
1150	Epidemiology of heart failure with preserved ejection fraction. 2014 , 10, 377-88	66
1149	Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. 2014 , 10, 481-501	27
1148	Clinical trials in patients with heart failure and preserved left ventricular ejection fraction. 2014 , 10, 511-23	31
1147	Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. 2014 , 16, 545	22
1146	Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. 2014 , 168, 721-30	212
1145	New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction. 2014 , 11, 374-81	4
1144	Renin-Angiotensin system blockade and worsening renal function in heart failure: an unfinished story. 2014 , 64, 1114-6	3
1143	Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. 2014 , 11, 1684-90	32
1142	Angioedema related to Angiotensin inhibitors. 2014 , 27, 461-5	11

1141	Novel biomarkers in heart failure with preserved ejection fraction. 2014 , 10, 471-9	16
1140	Outcomes in patients with heart failure with preserved ejection fraction. 2014 , 10, 503-10	7
1139	Current therapeutic approach in heart failure with preserved ejection fraction. 2014 , 10, 525-38	11
1138	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. 2014 , 35, 2797-815	231
1137	The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. 2014 , 33, 888-909	157
1136	Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. 2014 , 16, 992-1001	93
1135	Misconceptions and facts about 'diastolic' heart failure. 2014 , 127, 1144-7	4
1134	Management strategies for heart failure with preserved ejection fraction. 2014 , 10, 591-8	10
1133	[Diastolic heart failure]. 2014 , 55, 663-8	1
1132	Smart textiles applied in emergency department patients with chest pain. 2014 ,	1
1131	Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. 2014 , 7, 590-5	97
1130	Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. 2014 , 115, 79-96	322
1129	Newest additions to heart failure treatment. 2014 , 15, 1849-61	1
1128	Epidemiology of heart failure with preserved ejection fraction. 2014 , 11, 354-65	70
1127	New Insights Into Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction. 2014 , 18, 208-17	9
1126	Understanding the epidemic of heart failure: past, present, and future. 2014 , 11, 404-15	118
1125	Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. 2014 , 114, 862-8	25
1124	Contemporary strategies in the diagnosis and management of heart failure. 2014 , 89, 662-76	18

1123	[Extrapolation of results from clinical trials to heart failure patients hospitalized in Internal Medicine]. 2014 , 142, 463-7	
1122	Heart failure with preserved ejection fraction: looking for new pieces of a complex puzzle. 2014 , 107, 73-6	2
1121	Functional capacity in heart failure with preserved ejection fraction: looking for interactions and explanations. 2014 , 172, 295-6	1
1120	Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. 2014 , 2, 123-30	60
1119	Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. 2014 , 174, 268-75	105
1118	Heart failure with preserved ejection fraction: current understandings and challenges. 2014 , 16, 501	27
1117	Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. 2014 , 19, 681-94	104
1116	Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. 2014 , 7, 288-99	139
1115	Heart failure with preserved ejection fraction. 2014 , 12, 743-50	6
1114	Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. 2014 , 20, 560-8	33
1113	Modulation of the renin-angiotensin-aldosterone system in heart failure. 2014 , 16, 403	13
1112	Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Japan. Report from the CHART-2 study. 2014 , 78, 428-35	41
1111	Prediction of congestive heart failure in patients with non valvular atrial fibrillation. 2014 , 53, 7-12	8
1110	Sex- and gender-specific research priorities for the emergency management of heart failure and acute arrhythmia: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research Workgroup. 2014 , 21, 1361-9	7
1109	Impact Of Sex On Clinical Characteristics And In-Hospital Outcomes In A Multi-Ethnic Southeast Asian Population Of Patients Hospitalized For Acute Heart Failure. 2014 , 22, 8	4
1108	Old spontaneously hypertensive rats gather together typical features of human chronic left-ventricular dysfunction with preserved ejection fraction. 2014 , 32, 1307-16	12
1107	EARLY CLINICAL PROGNOSIS FOR HIGH-RISK CHEST PAIN PATIENTS USING SMART TEXTILES. 2015 , 27, 1550057	4
1106	Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction. 2015 , 2, 41-45	10

1105	Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study). 2015 , 38, 1404-9	5
1104	Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. 2015 , 79, 574-82	40
1103	Noncardiac comorbidities in heart failure with preserved ejection fraction - commonly ignored fact. 2015 , 79, 954-9	22
1102	Current challenges in the management of heart failure. 2015 , 79, 948-53	23
1101	Left Ventricular Ejection Fraction (EF) of 55% as Cutoff for Late Transition From Heart Failure (HF) With Preserved EF to HF With Mildly Reduced EF. 2015 , 79, 2209-15	28
1100	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. 2016 , 130, 57-77	149
1099	Towards 'Eternal Youth' of cardiac and skeletal muscle. 2015 , 2015, 12	
1098	Contribution of serotonin to cardiac remodeling associated with hypertensive diastolic ventricular dysfunction in rats. 2015 , 33, 2310-21	17
1097	Update of treatment in chronic heart failure. 2015 , 145, 545-550	
1096	Diagnostic accuracy of 64 slice multidetector coronary computed tomographic angiography in left ventricular systolic dysfunction. 2015 , 8, 42-46	1
1095	Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database. 2015 , 15, 134	27
1094	Strategies to Reduce Heart Failure Hospitalizations and Readmissions: How Low Can We Go?. 2015 , 1, 5-12	
1093	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. 2015 , 17, 848-74	27
1092	Geographic differences in heart failure trials. 2015 , 17, 893-905	53
1091	Reclassifying heart failure: time for disruptive innovation?. 2015 , 17, 879-80	3
1090	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. 2015 , 17, 925-35	120
1089	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. 2015 , 17, 1231-9	59
1088	Heart Failure With Preserved Ejection Fraction: What Is in a Name?. 2015 , 23, 161-7	8

1087	Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. 2015 , 30, 250-8	18
1086	Outcomes of heart failure with preserved ejection fraction in a Southeast Asian cohort. 2015 , 16, 583-90	5
1085	New diagnostic perspectives on heart failure with preserved ejection fraction: systolic function beyond ejection fraction. 2015 , 16, 527-37	7
1084	Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction. 2015 , 2015, 825027	12
1083	Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians. 2015 , 50, 454-9	6
1082	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. 2015 , 11, 283-95	15
1081	Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania. 2015 , 10, 979-90	7
1080	A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction. 2015 , 10, e0117332	33
1079	Assessment of transthyretin combined with mini nutritional assessment on admission provides useful prognostic information in patients with acute decompensated heart failure. 2015 , 56, 226-33	13
1078	New Insights in the Diagnosis and Treatment of Heart Failure. 2015 , 2015, 265260	9
1077	Treatment Modalities for Heart Failure with Preserved Ejection Fraction (HFpEF) - Current State of Evidence and Future Perspective. 2015 , 06,	
1076	Recent advances in treatment of heart failure. 2015 , 4,	8
1075	Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". 2015 , 7, 544-54	7
1074	Is blockade of the Renin-Angiotensin system able to reverse the structural and functional remodeling of the left ventricle in severe aortic stenosis?. 2015 , 65, 233-40	12
1073	Inflammation in Heart Failure with Preserved Ejection Fraction. 2015 , 3-18	3
1072	Heart Failure Controversies. 2015 , 423-431	
1071	βBlocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. 2015 , 66, 189-94	12
1070	Are angiotensin-converting enzyme inhibitors or angiotensin 2 receptor antagonists effective in heart failure with preserved ejection fraction?. 2015 , 15, e6101	1

1069	Sudden Cardiac Death in Coronary Artery Disease. 2015 , 621-656	
1068	Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure: is this enough?. 2015 , 1, 189-90	1
1067	Azilsartan, but not Candesartan Improves Left Ventricular Diastolic Function in Patients with Hypertension and Heart Failure. 2015 , 9, 201-205	8
1066	Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. 2015 , 66, 2757-2766	38
1065	Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. 2015 , 66, 2648-2662	57
1064	Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study. 2015 , 94, e1751	7
1063	Heart failure with preserved ejection fraction: refocusing on diastole. 2015 , 179, 430-40	73
1062	The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. 2015 , 38, 33-54	75
1061	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. 2015 , 131, 34-42	534
1060	Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction. 2015 , 183, 33-8	20
1059	Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. 2015 , 131, 1247-59	367
1058	Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. 2015 , 36, 915-23	41
1057	Diastolische Herzinsuffizienz. 2015 , 9, 315-328	
1056	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. 2015 , 31, 1282-92	9
1055	Spironolactone in patients with heart failure and preserved ejection fraction. 2015 , 215, 301-7	2
1054	Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. 2015 , 131, 7-10	20
1053	Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction. 2015 , 116, 508-14	6
1052	Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients!. 2015 , 41, 446-55	9

1051	Spironolactone in patients with heart failure and preserved ejection fraction. 2015 , 215, 301-307	
1050	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. 2015 , 3, 603-14	26
1049	The role of coronary microvascular disorder in congestive heart failure. 2015 , 308, H814-5	2
1048	Low Fitness in Midlife: A Novel Therapeutic Target for Heart Failure with Preserved Ejection Fraction Prevention. 2015 , 58, 87-93	20
1047	Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. 2015 , 128, 1275-80	49
1046	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. 2015 , 132, 402-14	263
1045	Heart failure management in skilled nursing facilities: a scientific statement from the American Heart Association and the Heart Failure Society of America. 2015 , 8, 655-87	38
1044	Heart Failure with Preserved Ejection Fraction. 2015 , 4, 283-296	
1043	Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure. 2015 , 16, 119-25	4
1042	Heart failure management in skilled nursing facilities: a scientific statement from the American Heart Association and the Heart Failure Society of America. 2015 , 21, 263-99	27
1041	Heart failure with preserved ejection fraction in the elderly: scope of the problem. 2015 , 83, 73-87	94
1040	Patient selection in heart failure with preserved ejection fraction clinical trials. 2015 , 65, 1668-1682	89
1039	LCZ696: the next step in improving RAS inhibition?. 2015 , 17, 37	7
1038	Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. 2015 , 13, 10	22
1037	Pharmacotherapy of heart failure with preserved ejection fraction. 2015 , 35, 351-60	17
1036	Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 9, 453-98	39
1035	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). 2015 , 3, 429-441	48
1034	[New therapy concepts for heart failure with preserved ejection fraction]. 2015 , 40, 194-205	1

1033	Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. 2015 , 8, 33-40	270
1032	Update on management of heart failure with preserved ejection fraction. 2015 , 30, 173-178	5
1031	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 65, 1372-407	76
1030	"Frailty, thy name is woman": syndrome of women with heart failure with preserved ejection fraction. 2015 , 8, S48-51	8
1029	Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 65, 1998-2038	97
1028	Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 2015 , 131, e435-70	80
1027	Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. 2015 , 116, 155-61	28
1026	The cost-effectiveness of irbesartan for hypertension. 2015 , 15, 199-207	1
1025	Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. 2015 , 20, 643-53	50
1024	Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction. 2015 , 132, 1719-25	94
1023	[Diastolic heart failure and multimorbidity]. 2015 , 140, 402-5	1
1022	Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. 2015 , 4, e002137	41
1021	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. 2015 , 373, 2314-24	331
1020	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. 2015 , 21, 674-93	28
1019	Heart failure with preserved ejection fraction: uncertainties and dilemmas. 2015 , 17, 665-71	97
1018	Can emergency physicians diagnose and correctly classify diastolic dysfunction using bedside echocardiography?. 2015 , 33, 1178-83	12
1017	Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. 2015 , 351, h4984	33
1016	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. 2015 , 17, 64	12

1015	Cardiac Imaging to Evaluate Left Ventricular Diastolic Function. 2015 , 8, 1071-1093	118
1014	Outcomes and worsening renal function in patients hospitalized with heart failure with preserved ejection fraction. 2015 , 116, 1534-40	21
1013	Management of Heart Failure. 2015 ,	1
1012	Management of heart failure with preserved ejection fraction: a review. 2015 , 37, 2186-98	25
1011	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. 2015 , 3, 478-486	17
1010	Improving outcomes in heart failure: a personal perspective. 2015 , 36, 3467-70	25
1009	[Update of treatment in chronic heart failure]. 2015 , 145, 545-50	1
1008	Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. 2015 , 28, 576-85	24
1007	Mineralocorticoids in the heart and vasculature: new insights for old hormones. 2015 , 55, 289-312	34
1006	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. 2015 , 443, 29-38	58
1005	Reversing heart failure-associated pathophysiology with exercise: what actually improves and by how much?. 2015 , 11, 17-28	19
1004	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 2015 , 131, 43-53	58
1003	Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. 2015 , 29, 241-6	19
1002	Handbook of Clinical Nutrition and Aging. 2015 ,	4
1001	Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction. 2015 , 30, 595-603	32
1000	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. 2015 , 36, 669-75	47
999	Cardio-Renal Clinical Challenges. 2015 ,	1
998	Renal Denervation. 2015 ,	2

997	ACEi and ARBS in Hypertension and Heart Failure. 2015 ,	1
996	Cardiac Drug Therapy. 2015 ,	2
995	Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. 2015 , 8, 286-94	209
994	Effect of Valsartan on Sarcoplasmic Reticulum Ca ²⁺ -ATPase Pump of the Left Ventricular Myocardium in Rats with Heart Failure with Preserved Ejection Fraction. 2016 , 1, 1-9	
993	Differential diagnosis and clinical management of diastolic heart failure: current best practice. 2016 , Volume 7, 117-135	0
992	Prognostic value of echocardiography and ECG in heart failure with preserved ejection fraction. 2016 , 117, 407-12	3
991	Heart Failure in Patients with Preserved Ejection Fraction: Questions Concerning Clinical Progression. 2016 , 3,	4
990	Targeting heart failure with preserved ejection fraction: current status and future prospects. 2016 , 12, 129-41	19
989	MicroRNA and Heart Failure. 2016 , 17, 502	82
988	Heart Failure: Diagnosis, Management and Utilization. 2016 , 5,	148
987	Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part I. 2016 , 31, 101-13	2
986	Activation of Peroxisome Proliferator-activated Receptor α Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt- β -catenin Signaling as a Possible Mechanism. 2016 , 68, 155-61	15
985	Contemporary clinical trial updates in heart failure. 2016 , 31, 349-55	1
984	Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications. 2016 , 349, 399-409	5
983	Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients. 2016 , 41, 873-885	2
982	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. 2016 , 9,	78
981	Circulating ACE2 activity correlates with cardiovascular disease development. 2016 , 17,	56
980	Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. 2016 , 3, MR000043	21

979	Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor- α activation in an obese rat model. 2016 , 12, 272-278	3
978	The Three-Decade Long Journey in Heart Failure Drug Development. 2017 , 243, 1-14	6
977	Diagnosis and management of heart disease in the elderly. 2016 , 157-186	
976	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. 2016 , 69, 1167.e1-1167.e85	91
975	The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians. 2016 , 92, 346-55	5
974	Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. 2016 , 16, 246	26
973	Contemporary Pharmacological Treatment of Heart Failure. 2016 , 207-227	
972	Understanding heart failure with preserved ejection fraction: where are we today?. 2016 , 24, 227-36	52
971	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2016 , 37, 2129-2200	7751
970	Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. 2016 , 68, 476-532	233
969	After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. 2016 , 37, 3135-3140	18
968	How big a problem is heart failure with a normal ejection fraction?. 2016 , 353, 11706	10
967	Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction. 2016 , 67, 1815-1825	115
966	Constrictive Pericarditis Versus Restrictive Cardiomyopathy?. 2016 , 67, 2061-76	58
965	Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations. 2016 , 1, 180-189	35
964	Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice. 2016 , 38, 379-391	10
963	Turning the Retrospectroscope on Heart Failure With Preserved Ejection Fraction. 2016 , 22, 1023-1027	2
962	Personalized Computer Simulation of Diastolic Function in Heart Failure. 2016 , 14, 244-52	5

961	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). 2016 , 220, 750-8	8
960	Diastolic dysfunction in the critically ill patient. 2016 , 40, 499-510	6
959	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. 2016 , 16, 116	33
958	Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data. 2017 , 32, 2043-2051	22
957	Reframing the association and significance of co-morbidities in heart failure. 2016 , 18, 744-58	116
956	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: Rationale and Study Design of a Prospective Randomized Controlled Trial. 2016 , 39, 433-9	7
955	Heart failure with normal ejection fraction is uncommon in acute myocardial infarction settings but associated with poor outcomes: a study of 91,360 patients admitted with index myocardial infarction between 1998 and 2010. 2016 , 18, 46-53	16
954	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. 2016 , 18, 54-65	57
953	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2016 , 18, 891-975	4036
952	Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. 2016 , 173, 1911-24	13
951	Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists. 2016 , 29, 52-61	7
950	Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?. 2016 , 133, 147-58	20
949	Comparison of Left Ventricular Relaxation and Left Atrial Function in Patients With Heart Failure and Preserved Ejection Fraction Versus Patients With Systemic Hypertension and Healthy Subjects. 2016 , 118, 1019-23	7
948	What constitutes optimal neurohumoral antagonism in chronic heart failure?. 2016 , 102, 1922-1932	2
947	Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study. 2016 , 16, 232	48
946	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. 2016 , 9,	25
945	Influence of Left Ventricular Ejection Fraction on the Effects of Supplemental Use of Angiotensin Receptor Blocker Olmesartan in Hypertensive Patients With Heart Failure. 2016 , 80, 2155-64	9
944	Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. 2016 , 18, 1508-1517	41

943	Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction. 2016 , 9,	66
942	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. 2017 , 38, 742-750	25
941	Diastolic dysfunction in the critically ill patient. 2016 , 40, 499-510	2
940	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. 2016 , 68, 2217-2228	157
939	If Exercise Is the Best Medicine, Should Medicine Be More Focused on Exercise in HFpEF?. 2016 , 68, 1835-1837	
938	Pulmonary Hypertension in Heart Failure Patients Presenting at OAUTHC, Ile-Ife, Nigeria. 2016 , 10, 187-193	
937	Renal function, serum sodium level, and outcomes in hospitalized systolic heart failure patients: An analysis of the COAST study. 2016 , 95, e3898	2
936	Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions. 2016 , 32, 1097-107	14
935	Myocardial reverse remodeling: how far can we rewind?. 2016 , 310, H1402-22	23
934	Mega clinical trials which have shaped the RAS intervention clinical practice. 2016 , 10, 133-50	31
933	The Established Therapies: HF-PEF and HF-REF. 2016 , 1-27	
932	Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. 2016 , 4, 502-10	32
931	Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. 2016 , 15, 48	7
930	Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. 2016 , 220, 56-60	18
929	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. 2016 , 134, 73-90	485
928	Association between coronary artery calcification and left ventricular diastolic dysfunction in elderly people. 2016 , 31, 499-507	13
927	Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF). 2016 , 22, 539-44	19
926	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. 2016 , 37, 455-62	217

925	Semiparametric regression for the weighted composite endpoint of recurrent and terminal events. 2016 , 17, 390-403	15
924	Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. 2016 , 102, 278-84	66
923	A Critical Evaluation of the Representation of Black Patients With Heart Failure and Preserved Ejection Fraction in Clinical Trials: A Literature Review. 2016 , 31, 202-8	2
922	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. <i>Lancet, The</i> , 2016 , 387, 1298-304 ⁴⁰	166
921	Chronic Heart Failure in Congenital Heart Disease: A Scientific Statement From the American Heart Association. 2016 , 133, 770-801	199
920	Heart failure - what the general physician needs to know. 2016 , 16, 25-33	1
919	Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. 2016 , 5,	54
918	New Management Strategies in Heart Failure. 2016 , 118, 480-95	23
917	Multimorbidity in Older Adults with Heart Failure. 2016 , 32, 277-89	18
916	Heart Failure With Preserved Ejection Fraction. 2016 , 41, 145-88	80
915	Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. 2016 , 9, e001937	47
914	Heart failure with preserved ejection fraction: A clinical crisis. 2016 , 204, 198-9	11
913	Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. 2016 , 21, 285-97	19
912	Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. 2016 , 205, 65-71	20
911	Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. 2016 , 9, e002724	38
910	Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. 2016 , 4, 140-149	38
909	Defining HFpEF: where do we draw the line?. 2016 , 37, 463-5	18
908	International Conference for Innovation in Biomedical Engineering and Life Sciences. 2016 ,	2

907	Effects of renin-angiotensin-aldosterone system inhibitors on mortality, hospitalization, and diastolic function in patients with HFpEF. A meta-analysis of 13 randomized controlled trials. 2016 , 41, 76-86	14
906	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. 2016 , 18, 12-36	37
905	Patients with left ventricular ejection fraction greater than 58 % have fewer incidences of future acute decompensated heart failure admission and all-cause mortality. 2016 , 31, 734-43	16
904	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach. 2017 , 10,	56
903	Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists. 2017 , 13, 156-161	
902	Short Stay Management of Acute Heart Failure. 2017 ,	
901	Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. 2017 , 232, 86-92	13
900	New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure. 2017 , 110, 1-6	2
899	Heart Failure with Preserved Ejection Fraction: Diagnosis and Management. 2017 , 130, 510-516	25
898	Heart Failure. 2017 , 93-141	
897	Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. 2017 , 18, 399-409	11
896	Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. 2017 , 21, 1742-1750	11
895	Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 1): Physiologic and Technical Considerations. 2017 , 10, 245-259	15
894	Heart Failure With Preserved Ejection Fraction: An Opportunity for Reflection. 2017 , 6,	1
893	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. 2017 , 19, 12	14
892	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. 2017 , 14, 59-70	38
891	Towards Precision in HF Pharmacotherapy. 2017 , 14, 1-6	3
890	The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis. 2017 , 96, e6525	1

889	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. 2017 , 14, 197-202	11
888	Arterial stiffness and elevated left ventricular filling pressure in patients at risk for the development or a previous diagnosis of HF-A subgroup analysis from the DIAST-CHF study. 2017 , 11, 303-313	13
887	Contemporary Approaches to Patients with Heart Failure. 2017 , 35, 261-271	15
886	Heart failure with preserved ejection fraction: a nephrologist-directed primer. 2017 , 22, 765-773	12
885	Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function. 2017 , 6,	16
884	Epidemiology of heart failure with preserved ejection fraction. 2017 , 14, 591-602	459
883	Heart Failure Guidelines on Pharmacotherapy. 2017 , 243, 109-129	6
882	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. 2017 , 243, 360-366	24
881	Targets for Heart Failure With Preserved Ejection Fraction. 2017 , 102, 228-237	12
880	Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings. 2017 , 23, 517-524	13
879	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017 , 23, 628-651	378
878	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017 , 136, e137-e161	1503
877	Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). 2017 , 14, 187-196	4
876	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017 , 70, 776-803	1064
875	Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. 2017 , 10,	33
874	Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial. 2017 , 19, 1067-1074	25
873	Association of renin-angiotensin-aldosterone system gene polymorphisms with left ventricular hypertrophy in patients with heart failure with preserved ejection fraction: A case-control study. 2017 , 39, 371-376	11
872	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). 2017 , 136, 982-992	55

871	Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. 2017 , 10, 233-244	40
870	Heart Failure. 2017 ,	4
869	Heart Failure Complicating Acute Myocardial Infarction. 2017 , 13, 513-525	4
868	Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. 2017 , 125, 57-71	71
867	Diagnosis and Management of Heart Failure in Older Adults. 2017 , 13, 427-444	7
866	Heart Failure with Preserved Ejection Fraction in Older Adults. 2017 , 13, 485-502	38
865	Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). 2017 , 119, 1763-1769	22
864	Diastolic dysfunction in hypertension. 2017 , 34, 128-139	6
863	Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. 2017 , 17, 283-298	6
862	Response to Endurance Exercise Training in Older Adults with Heart Failure with Preserved or Reduced Ejection Fraction. 2017 , 65, 1698-1704	28
861	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. 2017 , 33, 768-776	8
860	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. 2017 , 10,	13
859	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. 2017 , 19, 1615-1623	90
858	Current Pharmacological Therapies in Heart Failure Patients. 2017 , 24, 107-114	15
857	Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. 2017 , 6,	106
856	Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). 2017 , 19, 1586-1596	82
855	Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. 2017 , 106, 359-368	45
854	Ω-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. 2017 , 103, 74-92	40

853	Exercise-Based Rehabilitation for Heart Failure: Clinical Evidence. 2017 , 1000, 31-49	16
852	Skeletal muscle alterations in HF _r EF vs. HF _p EF. 2017 , 14, 489-497	19
851	Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. 2017 , 5, 763-771	103
850	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. 2017 , 70, 2186-2200	107
849	RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan. 2017 , 21, 326-333	0
848	Pharmacologic Management for Heart Failure and Emerging Therapies. 2017 , 19, 94	7
847	Seventeen-Year Nationwide Trends in Antihypertensive Drug Use in Denmark. 2017 , 120, 2193-2200	12
846	The Initial Evaluation and Management of a Patient with Heart Failure. 2017 , 19, 103	
845	Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 2017 , 4, 402-408	32
844	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 2017 , 33, 1342-1433	330
843	Prognostic Significance of Low Systolic Blood Pressure at Discharge in Patients with Heart Failure and Preserved Ejection Fraction. 2017 , 24, 405-412	
842	Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium. 2017 , 190, 76-85	14
841	Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. 2017 , 5, 565-574	148
840	A screening echocardiogram to identify diastolic dysfunction leads to better outcomes. 2017 , 34, 1152-1158	8
839	Kyoto Congestive Heart Failure (KCHF) study: rationale and design. 2017 , 4, 216-223	28
838	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. 2017 , 14, 434-443	13
837	The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients. 2017 , 12, 1093-1099	5
836	Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance. 2017 , 10,	13

835	A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function. 2017 , 7, 16587	17
834	Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. 2017 , 65, 2431-2440	38
833	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. 2017 , 6,	55
832	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. 2017 , 24, 463-472	12
831	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. 2017 , 5, 471-482	176
830	Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. 2017 , 22, 775-782	24
829	Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. 2017 , 10, 322-336	27
828	What's new in heart failure therapy 2018?. 2018 , 27, 921-930	4
827	[Noble Heart Failure Therapy Using Food Compositions]. 2018 , 138, 1263-1269	3
826	Impact of the duration of the evidence-based medicine use in acute heart failure: A nationwide cohort study. 2018 , 13, e0205440	
825	Redefining heart failure phenotypes based on ejection fraction. 2018 , 20, 1634-1635	6
824	Cardiology Consult Manual. 2018 ,	
823	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018 , 12, 579.e1-579.e73	83
822	Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves. 2018 , 32, 577-580	1
821	Entresto, a New Panacea for Heart Failure?. 2018 , 16, 5-11	6
820	What Proportion of Patients With Heart Failure and Left Ventricular Ejection Fraction 40% to 49% Fulfill the Criteria for Heart Failure With Mid-Range Ejection Fraction?. 2018 , 122, 2166-2167	0
819	Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. 2018 , 25, 1268-1277	8
818	Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction. 2018 , 20, 1240-1242	2

817	Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction. 2018 , 268, 166-169	3
816	Regional Cardiac Sympathetic Nervous System Evaluation Using 123I-mIBG SPECT in Patients with Heart Failure. 2018 , 49, 397-405	8
815	Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial. 2018 , 32, 381-388	2
814	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. 2018 , 6, CD012721	37
813	Heart Failure. 2018 , 3-16	
812	Heart failure with preserved ejection fraction: A systemic disease linked to multiple comorbidities, targeting new therapeutic options. 2018 , 111, 766-781	14
811	Characteristics of clinical drugs for elderly chronic heart failure complicated with different degrees of renal insufficiency. 2018 , 34, 135-138	2
810	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). 2018 , 5, 830-841	20
809	Long-Term Outcomes of Adults With Heart Failure by Left Ventricular Systolic Function Status. 2018 , 122, 1008-1016	8
808	Heart Failure. 2018 , 168, ITC81-ITC96	5
807	Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. 2018 , 6, 619-632	72
806	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. 2018 , 39, 3417-3438	29
805	Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. 2018 , 20, 1385-1391	24
804	Renin Angiotensin Aldosterone System Blockers. 2018 , 230-241	1
803	Sex Differences in Heart Failure. 2018 , 1065, 529-544	30
802	Association Trends Between Antihypertensive Drug Therapies and Diastolic Hypotension in Emirati Patients with Type 2 Diabetes: A Single-Center Retrospective Longitudinal Study. 2018 , 9, 1853-1868	
801	Perioperative management of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers: a survey of perioperative medicine practitioners. 2018 , 6, e5061	7
800	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. 2018 , 27, 1123-1208	141

799	Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. 2018 , 14, 890-909	34
798	Heart Failure With Preserved Ejection Fraction. 2018 , 464-468	
797	Heart Failure With Preserved Ejection Fraction. 2018 , 209-215	
796	Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. 2018 , 16, 579-589	17
795	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. 2018 , 11, e004962	70
794	Drug discovery with an RBM20 dependent titin splice reporter identifies cardenolides as lead structures to improve cardiac filling. 2018 , 13, e0198492	12
793	CSI position statement on management of heart failure in India. 2018 , 70 Suppl 1, S1-S72	12
792	Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study. 2018 , 53, 9-17	1
791	A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?. 2018 , 25, 1263-1267	2
790	Pharmacological management of hypertension in the elderly and frail populations. 2018 , 11, 805-817	2
789	Pulmonary Vascular Resistance During Exercise Predicts Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction. 2018 , 24, 169-176	16
788	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. 2018 , 72, 1081-1090	108
787	Neurohormonal Blockade. 2018 , 459-476	
786	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2018 , 72, e91-e226	411
785	Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. 2018 , 23, 609-629	19
784	Heart failure with preserved ejection fraction: from mechanisms to therapies. 2018 , 39, 2780-2792	155
783	Prognostic Significance of Baseline Serum Sodium in Heart Failure With Preserved Ejection Fraction. 2018 , 7,	9
782	Role of Aldosterone Receptor Antagonists in Heart Failure With Preserved Ejection Fraction. 2018 , 10, 1179559X1877135	0

781	Descent into heart and lung failure. 2018 , 3-36	1
780	Entrenamiento de la musculatura inspiratoria y la electroestimulaci3n muscular funcional en el tratamiento de la insuficiencia cardiaca con funci3n sist3lica conservada: estudio TRAINING-HF. 2019 , 72, 288-297	14
779	Group sequential designs for negative binomial outcomes. 2019 , 28, 2326-2347	6
778	Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force 3n Clinical Practice Guidelines. 2019 , 73, 1564-1578	12
777	Benefit-risk review of different drug classes used in chronic heart failure. 2019 , 18, 37-49	5
776	The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. 2019 , 124, 65-69	25
775	Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. 2019 , 53, 387-397	4
774	Heart failure with preserved ejection fraction in Asia. 2019 , 21, 23-36	64
773	Why Clinicians Should Care About the Cardiac Interstitium. 2019 , 12, 2305-2318	10
772	Perturbations of pulsatile hemodynamics and clinical outcomes in patients with acute heart failure and reduced, mid-range or preserved ejection fraction. 2019 , 14, e0220183	1
771	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). 2019 , 42, 1235-1481	468
770	Heart Failure in Women Due to Hypertensive Heart Disease. 2019 , 15, 497-507	3
769	Long-term outcome of hypertensive patients with heart failure with mid-range ejection fraction: The significance of blood pressure control. 2019 , 21, 1124-1131	3
768	Clinical Characteristics and Long-Term Outcomes of Patients with Acute Decompensated Heart Failure with Mid-Range Ejection Fraction. 2019 , 60, 862-869	3
767	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). 2019 , 74, 683-698	11
766	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. 2019 , 74, 601-612	40
765	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. 2019 , 21, 974-984	30
764	Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. 2019 , 10, 874	12

763	Burden and Causes of Hospital Admissions in Heart Failure During the Last Year of Life. 2019 , 7, 561-570	11
762	Clinical and Socioeconomic Predictors of Heart Failure Readmissions: A Review of Contemporary Literature. 2019 , 94, 1304-1320	11
761	Lumpers and splitters: the bumpy road to precision medicine. 2019 , 40, 3292-3296	11
760	Large Magnetoresistance in an Electric-Field-Controlled Antiferromagnetic Tunnel Junction. 2019 , 12,	8
759	Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. 2019 , 2019, 9246138	5
758	SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. 2019 , 8, e013389	78
757	PARAGON-HF - Why We Do Randomized, Controlled Clinical Trials. 2019 , 381, 1675-1676	7
756	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). 2019 , 124, 1912-1917	10
755	20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology. 2019 , 32, 1379-1395.e2	6
754	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. 2019 , 10, 1347	36
753	A Call for Change: Level of Statistical Significance. 2019 , 7, 993-994	2
752	Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction. 2019 , 6, 143	7
751	Dilated Cardiomyopathy With Mid-Range Ejection Fraction at Diagnosis: Characterization and Natural History. 2019 , 8, e010705	8
750	Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale. 2019 , 10, 2040622319868376	1
749	Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. 2019 , 381, 1609-1620	705
748	Prevalence and Incidence of Atrial Fibrillation in Ambulatory Patients With Heart Failure. 2019 , 124, 1554-1560	9
747	The PARAGON-Heart failure trial - another disappointment for heart failure patients with hypertension and preserved ejection fraction. 2019 , 28, 276-278	7
746	Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community. 2019 , 73, e13317	2

745	Hyponatremia at discharge is associated with adverse prognosis in acute heart failure syndromes with preserved ejection fraction: a report from the JASPER registry. 2019 , 8, 623-633	4
744	Different Impact of Changes in Left Ventricular Ejection Fraction Between Heart Failure Classifications in Patients With Acute Decompensated Heart Failure. 2019 , 83, 584-594	7
743	Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e801-e813	22
742	Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction - A report from the JASPER registry. 2019 , 73, 459-465	11
741	Obesity-related heart failure with preserved ejection fraction: new treatment strategies. 2019 , 47, 67-72	5
740	Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway. 2019 , 73, 2705-2718	21
739	Osteopontin in HFpEF: More Than Just a Remodeling-Specific Biomarker. 2019 , 73, 2719-2721	0
738	Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure. 2019 , 19, 597-605	7
737	[Heart failure with preserved ejection fraction (diastolic heart failure)]. 2019 , 161, 58-65	
736	Marginal hazard ratio estimates in joint frailty models for heart failure trials. 2019 , 61, 1385-1401	3
735	Evaluation of acute myocardial infarction patients with mid-range ejection fraction after emergency percutaneous coronary intervention. 2019 , 95, 355-360	0
734	Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity. 2019 , 24, 421-437	15
733	Heart failure with preserved ejection fraction in elderly. From pathophysiology to treatment: an unresolved problem. 2019 , 89,	1
732	Exercise in Heart Failure-What Is the Optimal Dose to Improve Pathophysiology and Exercise Capacity?. 2019 , 16, 98-107	10
731	The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/nepriylisin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. 2019 , 28, 215-216	1
730	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. 2019 , 124, 1520-1535	59
729	Medical Therapy for Heart Failure Associated With Pulmonary Hypertension. 2019 , 124, 1551-1567	24
728	Heart Failure With Preserved Ejection Fraction In Perspective. 2019 , 124, 1598-1617	229

727	Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. 2019 , 33, 461-470		31
726	Racial differences of heart failure with midrange ejection fraction (HFmrEF): a large urban centre-based retrospective cohort study in the USA. 2019 , 9, e026479		2
725	Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. 2019 , 20,		30
724	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. 2019 , 7, 418-427		10
723	Indications for BBlocker Prescriptions in Heart Failure with Preserved Ejection Fraction. 2019 , 67, 1461-1466		6
722	Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. 2019 , 24, 535-547		38
721	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2019 , 95, 1304-1317		96
720	Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction. 2019 , 49, 1505-1513		8
719	HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases. 2019 , 20,		36
718	Cardiac fibrosis: potential therapeutic targets. 2019 , 209, 121-137		65
717	Fimasartan for Remodeling after Myocardial Infarction. 2019 , 8,		1
716	Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. 2019 , 13, 38-46		18
715	Heart failure drug treatment. <i>Lancet, The</i> , 2019 , 393, 1034-1044	40	135
714	Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. <i>Lancet, The</i> , 2019 , 393, 1045-1055	40	33
713	A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats. 2019 , 129, 257-265		7
712	Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction. 2019 , 8, e011077		36
711	Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry. 2019 , 49, 238-248		6
710	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. 2019 , 12, e005766		14

709	Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. 2019 , 21, 20	19
708	Hypertension and Heart Failure. 2019 ,	
707	The Role of Drug Therapy in Lowering Mortality and Morbidity: From Established Heart Failure to High-Risk Hypertension. 2019 , 245-260	
706	Prevention and Treatment of Heart Failure in Hypertension Guidelines. 2019 , 393-402	
705	Ejercicio aeróbico en pacientes con falla cardiaca con y sin disfunción ventricular en un programa de rehabilitación cardiaca. 2019 , 26, 162-168	
704	Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design. 2019 , 212, 36-44	23
703	Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis. 2019 , 42, 641-649	5
702	Sex differences in left ventricular afterload and diastolic function are independent from the aortic size. 2019 , 14, e0214907	4
701	Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. 2019 , 42, 504-513	9
700	Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome?. 2019 , 7, 192-203	23
699	Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. 2019 , 105-120	
698	[Heart failure in patients over 80 years old]. 2019 , 48, 143-153	2
697	Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. 2019 , 3, 1-13	37
696	Hyperkalaemia: aetiology, epidemiology, and clinical significance. 2019 , 21, A6-A11	13
695	Myocardial Scar and Fibrosis: The Ultimate Mediator of Outcomes?. 2019 , 15, 179-189	8
694	Heart Failure. 2019 ,	
693	Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence. 2019 , 25, 25	1
692	Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction. 2019 , 98, e17069	7

691	Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs. 2019 , 8,	20
690	Association of β -Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. 2019 , 2, e1916598	32
689	Is PARAGON a Paragon Example of an HFpEF Clinical Trial?: A Call for Deep Phenotyping. 2019 , 74, 2874-2877	
688	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version. 2019 , 83, 2084-2184	228
687	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. 2019 , 12, e006539	36
686	Vive les Differences!-A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?. 2019 , 73, e13307	
685	Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance. 2019 , 151, 42-52	25
684	Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease - Report From the JASPER Study. 2019 , 83, 357-367	17
683	Heart Failure with Preserved Ejection Fraction in Women. 2019 , 15, 9-18	16
682	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2019 , 117-138.e7	1
681	Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. 2019 , 34, 597-606	7
680	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. 2019 , 6, 62-69	34
679	Contemporary Management of Heart Failure in the Elderly. 2019 , 36, 137-146	7
678	Cardiovascular Diseases in the Very Elderly. 2019 , 113-130	
677	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. 2019 , 59, 41-63	15
676	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial. 2019 , 72, 288-297	4
675	Heart Failure With Preserved Ejection Fraction: Prevention and Management. 2019 , 13, 182-189	10
674	Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial. 2020 , 26, 64-72	9

673	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. 2020 , 26, 673-684	2
672	Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and meta-analysis. 2020 , 25, e12710	3
671	Treatment of Heart Failure with Preserved Ejection Fraction. 2020 , 568-585	
670	Heart Failure as a Consequence of Hypertension. 2020 , 333-346.e6	
669	Characteristics and outcomes of HFpEF with declining ejection fraction. 2020 , 109, 225-234	18
668	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. 2020 , 25, 31-42	25
667	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2020 , 41, 255-323	1360
666	Usefulness and clinical relevance of left ventricular global longitudinal systolic strain in patients with heart failure with preserved ejection fraction. 2020 , 25, 67-73	7
665	The Chronic stage. 2020 , 135-147	
664	Role of endothelial dysfunction in heart failure. 2020 , 25, 21-30	45
663	Imaging of Diastolic Dysfunction in Community-Based Epidemiological Studies and Randomized Controlled Trials of HFpEF. 2020 , 13, 310-326	7
662	Heart Failure With Mid-range Ejection Fraction. 2020 , 17, 1-8	14
661	Heart failure with preserved ejection fraction: Similarities and differences between women and men. 2020 , 304, 101-108	12
660	Heart failure with preserved ejection fraction: New approaches to diagnosis and management. 2020 , 43, 145-155	29
659	Heart failure with reduced and preserved ejection fraction in adult congenital heart disease. 2020 , 25, 569-581	8
658	Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. 2020 , 59, 1127-1146.e1	1
657	Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. 2020 , 22, 214-227	27
656	Full Issue PDF. 2020 , 13, I-CLXII	

655	Sudden cardiac death risk prediction in heart failure with preserved ejection fraction. 2020 , 17, 358-364	13
654	Medical Therapies for Heart Failure With Preserved Ejection Fraction. 2020 , 75, 23-32	25
653	Contemporary approach to treating heart failure. 2020 , 30, 507-518	3
652	Angiotensin Receptor-Nepriylsin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes. 2020 , 142, 1246-1248	
651	The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction. 2020 , 8, 697-698	1
650	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 2020 , 22, 2175-2186	8
649	Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure. 2020 , 37, 3839-3849	1
648	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. 2020 , 8, 961-972	4
647	Sex Differences in HFpEF. 2020 , 22, 1	
646	Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. 2020 , 7,	13
645	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. 2020 , 22, 2383-2392	41
644	Trends in cause-specific readmissions in heart failure with preserved vs. reduced and mid-range ejection fraction. 2020 , 7, 2894-2903	3
643	Angiotensin receptor-nepriylsin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. 2020 , 22, 1525-1530	2
642	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. 2020 , 113, 797-810	1
641	Sex-specific differences in access and response to medical and device therapies in heart failure: State of the art. 2020 , 63, 640-648	1
640	Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction. 2020 , 22, 82	5
639	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. 2020 , 12, e10865	33
638	Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients. 2020 , 7, 2711-2724	1

637	Impact of left ventricular ejection fraction on the effect of renin-angiotensin system blockers after an episode of acute heart failure: From the KCHF Registry. 2020 , 15, e0239100	3
636	Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations. 2020 , 16, 769-785	10
635	Atrial Functional Mitral and Tricuspid Regurgitation. 2020 , 22, 1	1
634	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. 2020 , 142, 1236-1245	32
633	Spirolactone: diuretic or disease-modifying drug in heart failure with preserved ejection fraction?. 2020 , 22, 1611-1614	2
632	Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. 2020 , 9, e015103	13
631	Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman. 2021 , 43, 878-883	1
630	Ejection fraction in heart failure revisited- where does the evidence start?. 2020 , 41, 2363-2365	13
629	ARNI in cardiovascular disease: current evidence and future perspectives. 2020 , 16, 505-515	2
628	Anabolic Hormones Deficiencies in Heart Failure With Preserved Ejection Fraction: Prevalence and Impact on Antioxidants Levels and Myocardial Dysfunction. 2020 , 11, 281	3
627	Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism. 2020 , 52, 178-190	0
626	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. 2020 , 63, 570-584	22
625	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. 2020 , 8, 618-626	6
624	Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload. 2020 , 5, 463-480	4
623	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. 2020 , 316, 172-179	8
622	Effect of renin-angiotensin system inhibition on cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. 2021 , 26, 1477-1484	2
621	Management of neurogenic orthostatic hypotension in the heart failure patient. 2020 , 227, 102691	3
620	Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction. 2020 , 9, e015026	16

619	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. 2020 , 75, 1644-1656	23
618	Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes. 2020 , 7, 811-824	5
617	Covariate adjusted reanalysis of the I-Preserve trial. 2020 , 109, 1358-1365	5
616	Evaluation and management of heart failure with preserved ejection fraction. 2020 , 17, 559-573	113
615	Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. 2020 , 7, 381-399	17
614	Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF: JACC Review Topic of the Week. 2020 , 75, 1074-1082	38
613	Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction. 2020 , 7, 2752-2761	4
612	Variability of Myocardial Strain During Isometric Exercise in Subjects With and Without Heart Failure. 2020 , 7, 111	3
611	How to slice the pie: heart failure subgroups and their clinical meaning. 2020 , 41, 2339-2343	
610	Regional adiposity and heart failure with preserved ejection fraction. 2020 , 22, 1540-1550	29
609	Heart Failure with Preserved Ejection Fraction-a Concise Review. 2020 , 22, 82	13
608	Response to beta-blockers and natriuretic peptide level in acute heart failure: analysis of data from the Korean acute heart failure registry. 2021 , 110, 1392-1403	1
607	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. 2020 , 22, 1065-1075	17
606	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. 2020 , 7, 2098-2112	14
605	Anemia, Mortality, and Hospitalizations in Heart Failure With a Preserved Ejection Fraction (from the TOPCAT Trial). 2020 , 125, 1347-1354	8
604	Pharmacological interventions for heart failure in people with chronic kidney disease. 2020 , 2, CD012466	3
603	Tratamiento de la insuficiencia cardiaca en el paciente diabético: ¿Cuáles son las diferencias?. 2020 , 27, 26-32	
602	Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial. 2020 , 90, 105937	6

601	Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction. 2020 , 125, 1187-1193	14
600	Heart Failure With Preserved Ejection Fraction: Separating the Wheat From the Chaff. 2020 , 75, 255-257	2
599	An overview of hypertension and cardiac involvement in Asia: Focus on heart failure. 2020 , 22, 423-430	14
598	Substance and Substrate: LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials. 2020 , 141, 362-366	7
597	Managing heart failure with preserved ejection fraction. 2020 , 8, 395	6
596	Atrial fibrillation in patients with heart failure with preserved ejection fraction. 2020 , 35, 260-270	1
595	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. 2020 , 109, 1079-1098	41
594	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. 2020 , 41, 2356-2362	21
593	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. 2020 , 9,	7
592	Impact of the Geriatric Nutritional Risk Index on In-Hospital Mortality and Length of Hospitalization in Patients with Acute Decompensated Heart Failure with Preserved or Reduced Ejection Fraction. 2020 , 9,	10
591	Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. 2020 , 20, 188	1
590	From PARADIGM to PARAGON further evidence supporting continuous heart failure spectrum. 2020 , 22, 1536-1539	2
589	Specialty-Based Variability in Diagnosing and Managing Heart Failure With Preserved Ejection Fraction. 2020 , 95, 669-675	2
588	Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices. 2020 , 20, 266-271	
587	Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy. 2020 , 69, 77-87	1
586	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. 2021 , 35, 1839-1859	6
585	Predictors of outcome in patients with de novo diagnosis of heart failure with reduced ejection fraction: Role of combined myocardial and lung Iodine-123 Meta-Iodobenzylguanidine imaging. 2021 , 28, 72-85	1
584	Heart failure epidemiology and treatment in primary care: a retrospective cross-sectional study. 2021 , 8, 489-497	5

583	Clinical and echocardiographic characteristics of patients with preserved versus mid-range ejection fraction. 2021 , 37, 503-508	1
582	Renal Denervation to Treat Heart Failure. 2021 , 83, 39-58	9
581	Characteristics, prognosis and treatment response in distinct phenogroups of heart failure with preserved ejection fraction. 2021 , 323, 148-154	5
580	ABCs of Heart Failure (HFpEF) Management: Guide for Nurse Practitioners. 2021 , 17, 168-173	
579	Heart Failure With Midrange Ejection Fraction-What Is It, If Anything?. 2021 , 37, 585-594	1
578	SGLT2-inhibitors; more than just glycosuria and diuresis. 2021 , 26, 623-642	14
577	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. 2021 , 133, 125-139	3
576	The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. 2021 , 30, 683-691	11
575	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. 2021 , 110, 1234-1248	3
574	Association between evidence-based medication at discharge and outcomes in patients with heart failure: a systematic review and meta-analysis. 2021 , 26, 81-89	4
573	Echo-Based Approach to the Management of Heart Failure With Preserved Ejection Fraction. 2021 , 473-488	
572	Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence. 2021 , 10,	1
571	Transcatheter Interatrial Shunts for the Treatment of Heart Failure with Preserved Ejection Fraction. 2021 , 34, 81-88	
570	Cardiovascular Disease. 2021 , 239-260	
569	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. 2021 , 69, 1309-1318	2
568	The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction. 2021 , 42, 4621-4623	3
567	Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. 2021 , 118,	2
566	Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation. 2021 , 36, e252	

565 Korunmuş Ejeksiyon fraksiyonlu kalp yetmezliği 94-97

564 Heart Failure With Preserved Ejection Fraction. **2021**, 201-222

563 Ventricular-Arterial Interaction in Patients With Heart Failure and a Preserved Ejection Fraction. **2021**, 71-85

562 Power and sample size for multistate model analysis of longitudinal discrete outcomes in disease prevention trials. **2021**, 40, 1960-1971 0

561 Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. **2021**, 6, 89-99 6

560 Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. **2021**, 372, n189 7

559 INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". **2021**, 18, 5-99 20

558 Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System. **2021**, 106, 3398-3412 0

557 Arterial Stiffness Index and Exercise Tolerance in Patients Undergoing Cardiac Rehabilitation. **2021**, 62, 230-237 2

556 Narrative review in the current role of angiotensin receptor-neprilysin inhibitors. **2021**, 9, 518 1

555 Phenotyping heart failure using model-based analysis and physiology-informed machine learning.

554 Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. **2021**, 23, 776-784 3

553 The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications.

552 The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. **2021**, 9, 169-178 10

551 Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. **2021**, 9, 523 1

550 Position of Patients with Mid-Range Ejection Fraction in the General Chronic Heart Failure Population. **2021**, 11, 111-121 1

549 Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?. **2021**, 36, 413-419 2

548 Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction. **2021**, 8, 678530 3

547	New horizons in cardiogeriatrics: geriatricians and heart failure care-the custard in the tart, not the icing on the cake. 2021 , 50, 1064-1068	1
546	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. 2021 , 135, 991-1007	1
545	A double-blinded, placebo-controlled randomized trial evaluating the efficacy and safety of Zhigancao Tang granules for treating HFpEF: study protocol for a randomized controlled trial. 2021 , 22, 293	1
544	Multioomic Profiling in Black and White Populations Reveals Novel Candidate Pathways in Left Ventricular Hypertrophy and Incident Heart Failure Specific to Black Adults. 2021 , 14, e003191	2
543	Seeking patient-centered trial outcomes: The case for days alive out of hospital. 2021 ,	1
542	Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failure. 2021 , 8, 3070-3081	3
541	Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?. 2021 , 8, 678121	2
540	Representation of Black patients in heart failure clinical trials. 2021 , 36, 329-334	1
539	Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study. 2021 , 77, 1569-1581	
538	Sex differences in the longitudinal relationship of low-grade inflammation and echocardiographic measures in the Hoorn and FLEMENGHO Study. 2021 , 16, e0251148	1
537	Caregivers of Patients with Heart Failure: Burden and the Determinants of Health-Related Quality of Life. 2021 , 15, 1153-1164	2
536	Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure. 2021 , 476, 3449-3460	1
535	Clinical assessment of endothelial function in heart failure with preserved ejection fraction: A meta-analysis with meta-regressions. 2021 , 51, e13552	5
534	Sex-related differences in the pharmacological treatment of heart failure. 2021 , 229, 107891	4
533	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. 2021 , 5, CD012721	3
532	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. 2021 , 39, 1522-1545	7
531	Falla cardiaca con fracci3n de eyecci3n preservada: generalidades y aproximaci3n en el perioperatorio. 2021 , 28, 49-60	
530	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. 2021 , 23, 1217-1225	39

529	Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis. 2021 ,	
528	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. 2021 , 36, 100933	14
527	Characterisation of haemodynamic and metabolic abnormalities in the heart failure spectrum: the role of combined cardiopulmonary and exercise echocardiography stress test. 2021 ,	9
526	Adverse Effects of Medications on Micronutrient Status: From Evidence to Guidelines. 2021 , 41, 411-431	1
525	Diving Into the Diagnostic Score Algorithms of Heart Failure With Preserved Ejection Fraction. 2021 , 8, 665424	1
524	Recent advances in pharmacological treatment of heart failure. 2021 , 51, e13624	5
523	Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. 2021 , 10, e018549	14
522	Survival in Patients With Nonischemic Cardiomyopathy With Preserved vs Reduced Ejection Fraction.. 2021 , 3, 1333-1340	0
521	Psychosocial factors, mental health, and coordination capacity in patients with heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction. 2021 , 8, 3268-3278	4
520	Left Ventricular Diastolic Function Studied with Magnetic Resonance Imaging: A Systematic Review of Techniques and Relation to Established Measures of Diastolic Function. 2021 , 11,	4
519	Heart failure with preserved ejection fraction based on aging and comorbidities. 2021 , 19, 291	1
518	Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options. 2021 , 12, 6-15	
517	Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study. 2021 , 15, 1693-1706	2
516	Hypertension and Heart Failure with Preserved Ejection Fraction. 2021 , 17, 337-343	2
515	Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. 2021 , 23, 1250-1255	8
514	Emerging trends in cardiovascular research: HFpEF in the spotlight. A bibliometric analysis of the years 2009-2016. 2021 , 112, 506-513	0
513	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. 2021 , 22,	2
512	Features of renal macrophage infiltration in patients with myocardial infarction. 2021 , 36, 61-69	1

511	Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: Two Chronic Troublemakers. 2021 , 17, 377-386	2
510	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. 2021 , 67, 89-97	2
509	RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. 2021 , 22,	1
508	Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction. 2021 , 17, 315-326	6
507	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. 2021 , 17, 463-482	0
506	Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. 2021 , 23, 1541-1551	7
505	Renal Dysfunction and Heart Failure with Preserved Ejection Fraction. 2021 , 17, 357-367	1
504	Survival analyses in cardiovascular research, part II: statistical methods in challenging situations. 2021 , 75, 77-77	3
503	Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis: Prognostic and Therapeutic Implications. 2021 , 17, 499-518	3
502	Can mechanical circulatory support be an effective treatment for HFpEF patients?. 2021 , 1	1
501	Molecular Signature of HFpEF: Systems Biology in a Cardiac-Centric Large Animal Model. 2021 , 6, 650-672	3
500	Prognostic Impact of Echocardiographic Diastolic Dysfunction on Outcomes in Patients With Heart Failure With Preserved Ejection Fraction - Insights From the PURSUIT-HFpEF Registry. 2021 ,	2
499	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study. 2021 , 8, 4243-4254	1
498	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. 2021 , 42, 3741-3752	13
497	[Update on diagnostics and treatment of heart failure]. 2021 , 1	
496	Role of angiotensin II in the development of subcellular remodeling in heart failure. 352-371	1
495	Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Events—Application to Clinical Trials in Chronic Heart Failure. 1-12	2
494	Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation. 2021 , 94, 73-84	0

493	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. 2021 , 385, 1451-1461	358
492	Iron therapy in iron-deficiency patients with heart failure with preserved ejection fraction: A protocol for meta-analysis. 2021 , 100, e26919	
491	Blood pressure visit-to-visit variability and outcomes in patients with heart failure with preserved ejection fraction. 2021 , 8, 3984-3996	1
490	Therapie der diastolischen Herzinsuffizienz (HFpEF/HFmrEF): Lichtstreifen am Horizont?. 2021 , 10, 310-315	
489	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 2021 , 42, 3599-3726	875
488	Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. 2021 , 3, 440-448	6
487	Análisis de supervivencia en investigación cardiovascular (II): metodología estadística en situaciones complejas. 2021 ,	2
486	Percutaneous edge-to-edge mitral valve repair for mitral regurgitation improves heart failure symptoms in heart failure with preserved ejection fraction patients. 2021 ,	1
485	Phenotyping heart failure using model-based analysis and physiology-informed machine learning. 2021 , 599, 4991-5013	1
484	Bariatric surgery decreases the number of future hospital admissions for diastolic heart failure in subjects with severe obesity: a retrospective analysis of the US National Inpatient Sample database. 2021 ,	1
483	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. 2021 , 27, 1404-1444	8
482	Pharmacogenomic study of heart failure and candesartan response from the CHARM programme.	
481	Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus. 2021 , 20, 180	4
480	Autonomic regulation device therapy in patients with heart failure with preserved ejection fraction. 2021 , 2, e0150	
479	Heart failure with mid-range or mildly reduced ejection fraction. 2021 ,	16
478	State-of-the-Art Review of Current Therapies for HFpEF: An Overview of Interatrial Septal Device Therapy in Heart Failure. 2021 , 17, e230421189012	1
477	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. 2021 , 85, 2252-2291	8
476	Methodological challenges in the analysis of recurrent events for randomised controlled trials with application to cardiovascular events in LEADER. 2021 ,	1

475	Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF. 2021 , 1867, 166208	4
474	Advanced Heart Failure in a Special Population: Heart Failure with Preserved Ejection Fraction. 2021 , 17, 685-695	0
473	Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials. 2021 , 241, 108-119	3
472	Biomaterials based cardiac patches for the treatment of myocardial infarction. 2021 , 94, 77-89	7
471	Coronary Artery Disease. 2021 , 308-321	
470	General Treatment of Heart Failure With Preserved Ejection Fraction and Randomized Trials. 2021 , 463-472	
469	Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. 2021 , 39, 1378-1385	2
468	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. 2021 , 323, 188-191	3
467	Diagnosis, Prevention, and Treatment of Hypertensive Heart Disease. 2014 , 51-58	1
466	Heart Failure with Preserved Ejection Fraction. 2015 , 213-230	2
465	Heart Disease in the Elderly. 2013 , 669-686	2
464	Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. 2014 , 259-289	4
463	Hypertension and Prevention of Diastolic Heart Failure in the Aging Population. 2014 , 35-45	3
462	Heart Failure in the Older Hypertensive Patient. 2005 , 197-228	1
461	Congestive Heart Failure. 2012 , 91-111	3
460	Diastolic Disturbances in Diabetes Mellitus. 2008 , 271-284	2
459	NHG-Standaard Hartfalen. 2009 , 193-212	1
458	Consensus document: management of heart failure in type 2 diabetes mellitus. 2021 , 26, 1037-1062	2

457	Left Ventricular Hypertrophy, Congestive Heart Failure, and Coronary Flow Reserve Abnormalities in Hypertension. 2005 , 250-280	1
456	Treatment of Hypertension in the Patient with Cardiovascular Disease * *Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; MI, myocardial infarction; ARB, angiotensin II type 1 receptor blocker; BB, beta-adrenergic receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; DBP, diastolic blood pressure; ESRD, end stage renal disease; HR, heart failure.; 2007 , 623-646	0
455	Acute and Chronic Heart Failure: Positive Inotropes, Vasodilators, and Digoxin. 2009 , 160-197	2
454	Heart Failure. 2010 , 171-179.e1	3
453	Heart Failure with Normal Ejection Fraction. 2012 , 586-600	0
452	Cardiovascular Disease in the Elderly. 2012 , 1727-1756	5
451	Increased myocardial stiffness more than impaired relaxation function limits cardiac performance during exercise in heart failure with preserved ejection fraction: a virtual patient study. 2020 , 1, 40-50	4
450	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. 2021 , 42, 700-710	35
449	The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. 2020 , 22, L77-L81	4
448	Heart Failure. 2009 , 835-876	3
447	Diastolic Heart Failure: A Review of Current and Future Treatment Options. 2021 , 29, 82-88	1
446	The Effects of Preserving Mitral Valve Function on a Left Atrial Assist Device: An In Vitro Mock Circulation Loop Study. 2021 , 67, 567-572	3
445	Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. 2018 , 3,	17
444	Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. 2015 , 12, 294-304	60
443	Heart failure in older adults: embracing complexity. 2016 , 13, 8-14	3
442	Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). 2006 , 29 Suppl, S1-105	190
441	Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction. 2013 , 8, e68893	50
440	The Management of Heart Failure with Preserved Ejection Fraction. 2015 , 1, 11-15	1

439	What the General Practitioner Needs to Know About Their Chronic Heart Failure Patient. 2016 , 2, 79-84	7
438	Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. 2020 , 6, e28	5
437	Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction. 2020 , 6, e27	3
436	Heart Failure with Preserved Ejection Fraction – A Review. 2012 , 9, 90-95	0
435	[Heart failure with preserved ejection fraction (diastolic heart failure)]. 2012 , 153, 2030-40	3
434	2020 Clinical practice guidelines for Chronic heart failure. 2020 , 25, 4083	95
433	Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis. 2020 , 53, e9646	5
432	[Gerontology Issues in Cardiology Practice]. 2019 , 59, 54-63	2
431	. 2018 , 58, 42-72	11
430	Old age, high risk medication, polypharmacy: a 'trilogy' of risks in older patients with atrial fibrillation. 2016 , 14, 706	22
429	Management of heart failure with preserved ejection fraction. 2020 , 43, 12-17	2
428	Candesartan in heart failure. 2006 , 1, 357-66	9
427	Valsartan in the treatment of heart attack survivors. 2006 , 2, 125-38	19
426	Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. 2008 , 4, 223-34	9
425	Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme Inhibitors. 2012 , 12, 263	4
424	Pulmonary Hypertension Out of Proportion to Left Heart Disease. 2006 , 5, 21-29	8
423	Angiotensin Type 1 Receptor Blockers in Heart Failure. 2020 , 21, 125-131	7
422	Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. 2015 , 11, 42-52	48

421	Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review. 2016 , 12, 180-5	12
420	High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac Disease. 2011 , 5, 188-95	5
419	Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials. 2020 , 2, 12	8
418	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. 2016 , 31, 1-14	10
417	Heart failure with preserved ejection fraction: insights from recent clinical researches. 2020 , 35, 514-534	4
416	Current status of heart failure: global and Korea. 2020 , 35, 487-497	12
415	Optimal Management of Heart Failure with Preserve Ejection Fraction. 2015 , 88, 135	1
414	Correlation Between Diastolic Dysfunction and Coronary Artery Disease on Coronary Computed Tomography Angiography. 2016 , 17, 13-8	9
413	Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. 2017 , 8, 124-131	8
412	Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. 2020 , 12, 7-25	16
411	Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction. 2010 , 2, 13-8	2
410	Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence. 2014 , 6, 67-76	14
409	Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats. 2019 , 26, 575-583	10
408	On the search for the right definition of heart failure with preserved ejection fraction. 2020 , 27, 449-468	5
407	The clinical quandary of left and right ventricular diastolic dysfunction and diastolic heart failure. 2010 , 21, 212-20	4
406	Systems biology applied to heart failure with normal ejection fraction. 2014 , 102, 510-7	3
405	Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure?. 2016 , 106, 121-9	5
404	Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease. 2020 , 9,	3

403	Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. 2021 , 12, 746494	8
402	Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients. 2021 ,	1
401	Differential impact of antihypertensive drugs on cardiovascular remodeling: a review of findings and perspectives for HFpEF prevention. 2021 ,	2
400	Hypertensive Heart Failure in Asia.. 2021 , 9, 47-56	2
399	Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction. 2021 , 2, e0162	
398	Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. 2021 , 8,	0
397	Beta-blockers are associated with reverse remodeling in patients with dilated cardiomyopathy and mid-range ejection fraction. 2021 , 11, 100053	
396	Heart failure in diabetes. 2021 , 125, 154910	15
395	????????????(5.???????? : ?????)(?67????????). 2003 , 11, 281-289	
394	Inhibitors of the RAS: Evidence-Based Medicine. 2004 , 545-592	
393	Clinical Pharmacology of Angiotensin II Receptor Antagonists. 2004 , 453-484	
392	ACE-Hemmer und Angiotensinrezeptorantagonisten. 2004 , 179-206	
391	Herzinsuffizienz. 2004 , 323-366	
390	Heart failure: an epidemic of the 21st century. 2004 , 3, 194-204	9
389	Ask the Experts. 2004 , 24, 67-69	
388	Diastolic Dysfunction: Pathophysiology, Clinical Features, and Treatment. 2005 , 271-301	
387	The benefits and pitfalls of evidence-based medicine. 2006 , 48, 24-31	3
386	The Data Monitoring Experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program. 2006 , 166-175	

385 Diastolic Heart Failure. **2006**, 227-246

384 Vasodilators in the Management of Heart Failure. **2006**, 99-112

383 The antidiabetic effect of angiotensin II receptor antagonists. **2006**, 85-98

382 Angiotensin II antagonists and protection against subclinical cardiac and vascular damage. **2006**, 111-126

1

381 Angiotensin receptor blockers for chronic heart failure. **2006**, 127-171

380 ?????????????? : ??????????????(6.????????????????????,70????????????). **2006**, 14, 290-297

379 Pathophysiology and Clinical Impact of Diastolic Heart Failure. **2007**, 1201-1215

378 Aging and the Cardiovascular System. **2007**, 2439-2451

377 Systolic and Diastolic Heart Failure in the Community. **2007**, 2007, 360-362

376 Pharmacologic Management of Heart Failure in the Ambulatory Setting. **2007**, 331-362

375 Etiology and Pathophysiology of Heart Failure. **2007**, 21-39

374 The Medical Management of Heart Failure. **2007**, 1397-1416

373 Cardiac disorders. **2007**, 399-428

372 Sudden Cardiac Death. **2007**, 2039-2083

371 Heart Failure. **2007**, 278-292

370 Medicamenteuze behandeling van chronisch hartfalen. **2007**, 123-137

369 Akute Herzinsuffizienz und kardiogener Schock, Herzbeuteltamponade. **2008**, 387-405

368 Heart failure: Back to basics for pharmacists. **2008**, 141, 48-57

367 Normal Physiology and Pathophysiology of Left Ventricular Diastole. **2008**, 52-62

366 Molecular Mechanisms of Diastolic Dysfunction. **2008**, 3-19

365 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2008**, 201-229

364 Heart Failure. **2008**, 542-576

363 Systemic Hypertension in the Elderly. **2008**, 137-158

362 Management of chronic heart failure. **2008**, 50, 259-267

361 Unique Aspects of Vascular and Cardiac Ultrasound in Racial/Ethnic Groups. **2009**, 247-268

360 Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. **2009**, 112-159

359 Which Therapy for Which Condition?. **2009**, 388-458

358 CORONARY ARTERY DISEASE. **2009**, 321-365

357 Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction. **2009**, 93-102

1

356 Heart failure with normal left ventricular ejection fraction (HFNEF). **2009**, 113-128

355 Hemmstoffe des Renin-Angiotensin-Systems. **2009**, 203-235

354 Chronic Heart Failure. **2009**, 333-353

353 ??????????. **2009**, 16, 439-445

352 Effect of renin-angiotensin system inhibitors in diabetic dialysis patients with chronic heart failure. **2009**, 42, 151-157

351 Echocardiographic assessment of left ventricular diastolic function: what we able to do in 2009. **2009**, 51, 789-804

350 Principles of Treatment and Pharmacotherapy. **2010**, 255-275

349 Acute Decompensated Cardiac Failure. **2010**, 323-342

348 Atrial Fibrillation and Heart Failure Syndromes. **2010**, 289-308

347 Hemmstoffe des Renin-Angiotensin-Systems. **2010**, 219-252

346 Advances in diastolic heart failure. **2010**, 2, 58-63

2

345 The Pharmacologic Management of Heart Failure. **2010**, 883-902

344 Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. **2010**, 250-262

343 Heart Failure of Aging: Clinical Considerations. **2010**, 341-349

342 NHG-Standaard Hartfalen. **2011**, 459-496

3

341 Akute Herzinsuffizienz und kardiogener Schock, Herzbeuteltamponade. **2011**, 391-409

340 Aldosterone blockade. **2011**, 253-257

339 Physiologic Changes in Cardiac Function with Aging. **2011**, 621-633

338 Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure. **2011**, 659-673

337 Cardiac Changes in the Elderly. **2011**, 279-292

336 Risk Factors for Atherosclerosis in the Elderly. **2011**, 635-648

335 Stabilizing unstable plaque in acute coronary syndromes. **2011**, 338-345

334 Plaque Passivation and Endothelial Therapy. **2011**, 289-298

333 Hemmstoffe des Renin-Angiotensin-Systems. **2011**, 225-260

332 Cardiovascular Pharmacology. **2011**, 235-295

1

331 Congestive Heart Failure. **2012**, 281-324

330 Healed Myocardial Infarction. **2012**, 349-364

329 Hyperkalemia Risk and Treatment of Heart Failure. **2012**, 81-99

328 Hyperkalemia Risk and Treatment of Heart Failure. **2012**, 23-41

327 Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. **2012**, 11-22

326 Evaluation and Management of Arrhythmias Associated with Congestive Heart Failure. **2012**, 819-822

325 Acute Decompensated Heart Failure. **2012**, 22-41

324 Pulsed and Tissue Doppler Echocardiographic Abnormalities in Patients with Diastolic Heart Failure with and without Atrial Fibrillation. **2012**, 03, 661-668

323 Does impaired glucose tolerance associate with heart failure?. **2012**, 18, 245-251

322 Ultraschalldiagnostik. **2012**, 438-465

321 Hemmstoffe des Renin-Angiotensin-Systems. **2012**, 225-262

320 Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. **2012**, 39-50

319 L'insuffisance cardiaque et son traitement : un enjeu pour les systèmes de santé **2012**, 196, 1159-1167

318 Patient, provider and system factors influencing rehospitalisation in adults with heart failure: a literature review.. 2772-2798

317 Drug therapies for heart failure. **2012**, 46-56

316 Heart Failure. 172-201

315 Heart Failure and Sudden Death. **2013**, 395-412

314 Prevalence of Atrial Fibrillation in Systolic Heart Failure, Pulsed and Tissue Doppler Echocardiographic Abnormalities. **2013**, 04, 504-509

- 313 Hemmstoffe des Renin-Angiotensin-Systems. **2013**, 217-256
- 312 Chronic Coronary Artery Disease. **2014**, 67-85
- 311 Complications cardiovasculaires macroangiopathiques et insuffisance cardiaque chez le diabétique. **2014**, 265-275
- 310 Hemmstoffe des Renin- Angiotensin-Systems. **2014**, 259-300
- 309 The RAAS in Heart Failure: An Update on Clinical Trials and Opportunities for Therapy. **2014**, 165-182
- 308 Left Heart Failure. **2014**, 209-221
- 307 Assessing strategies for heart failure with preserved ejection fraction at the outpatient clinic. **2014**, 103, 231-7 2
- 306 Statistical Approaches to Improving Trial Efficiency and Conduct. **2014**, 71-84
- 305 Angiotensin II receptor blockers in the treatment of arterial hypertension in patients with concomitant pathology: focus on candesartan. **2014**, 11, 24-29 2
- 304 Target Organ Damage and RAAS Blockade. **2015**, 119-148
- 303 How to Use Inhibitors of the Renin-Angiotensin-Aldosterone System in Patients with CKD and Heart Failure. **2015**, 163-170
- 302 Chronic Heart Failure. **2015**, 215-236
- 301 Renal Denervation for Congestive Heart Failure. **2015**, 163-173
- 300 Acute Decompensated Cardiac Failure. **2015**, 445-470
- 299 Neurohormonal Blockade in Heart Failure. **2015**, 77-111
- 298 Medicatie bij hartfalen. **2015**, 53-83
- 297 Hemmstoffe des Renin-Angiotensin-Systems. **2015**, 267-309 1
- 296 Epidemiology of Heart Failure. **2015**, 1-12

295 New therapy approach in heart failure with preserved ejection fraction based on new pathophysiological concept. **2016**, 35, 53-59

294 Follow-Up of the Hypertensive Patients with Cardiovascular Disease. **2016**, 261-277

293 Management of the Patient with Heart Failure with Preserved Ejection Fraction. **2017**, 125-148

292 Outpatient Medication Titration in Acute Heart Failure. **2017**, 243-258

291 Ultraschalldiagnostik in der Anästhesiologie. **2017**, 1-35

290 Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). **2017**, 273-339

289 Acute decompensated heart failure with preserved ejection fraction: focus on serelaxin. **2017**, 10, 26

288 Heart Failure. **2017**, 1-13

287 Neurohormonal Activation and the Management of Heart Failure. **2017**, 239-246

286 PharmacotherapyFirst: A Multimedia Learning Resource. **2017**,

285 Novelties in the treatment of heart failure. **2017**, 63, 255-264

2

284 Chronic Heart Failure. **2017**,

283 CANDESARTAN IN CARDIOLOGY PRACTICE. **2017**, 12-16

282 Comorbidity of Medical and Psychiatric Disorders in Geriatric Population. **2018**, 448-474

281 Traitement de l'insuffisance cardiaque. **2018**, 141-166.e2

280 Acute and Chronic Heart Failure. **2018**, 237-252

279 Cardiac Disease in Older Adults. **2018**, 1-21

278 Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction. **2018**, 12, 8-12

- 277 CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: TREATMENT IN CONDITIONS OF LIMITED EVIDENCE. **2018**, 25, 106-114
- 276 Fixed combinations in modern hypertension treatment algorithms. **2018**, 17, 86-94 1
- 275 Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique. **2019**, 377-390
- 274 Patterns of Treatment in Patients with Heart Failure with Preserved Ejection Fraction: the REasons for Geographic And Racial Differences in Stroke study.
- 273 Comorbidity of Medical and Psychiatric Disorders in Geriatric Population. **2019**, 528-555
- 272 Heart Failure with Preserved Ejection Fraction. **2019**, 397-408
- 271 Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future. **2020**, 114, 120-129 0
- 270 Therapie der chronischen Herzinsuffizienz. **2019**, 40,
- 269 Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF. **2019**, 2019, 3
- 268 1. Pharmacotherapy for Cardiovascular Disease: current status. **2019**, 50, 99-106
- 267 The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. **2019**, 98-111 3
- 266 [Heart failure with preserved ejection fraction. A dim light at the end of the tunnel]. **2019**, 54, 307-308 0
- 265 Encyclopedia of Gerontology and Population Aging. **2020**, 1-8
- 264 Biomarkers from Bench to Bedside and Back â Back-Translation of Clinical Studies to Preclinical Models. **2020**, 307-331
- 263 Heart Failure Drug Class Effects on 30-Day Readmission Rates in Patients with Heart Failure with Preserved Ejection Fraction: A Retrospective Single Center Study. **2020**, 7, 1
- 262 [Treatment of chronic heart failure: is deprescribing possible?]. **2020**, 60, 126-136
- 261 Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction. **2020**, 28, 100525 0
- 260 [Frequency of use and Indications for Beta-Blockers in Heart Failure with Preserved Ejection Fraction]. **2020**, 60, 30-40

- 259 Five-Year Outcomes of Heart Failure with Preserved Ejection Fraction. **2020**, 14, 18-26 1
- 258 Readmission Rates and Medication Selection for Patients with Heart Failure Preserved Ejection Fraction.
- 257 Pharmacological Treatment of Chronic Heart Failure. **2020**, 79, 209-215
- 256 [For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?]. **2021**, 42, 814-815
- 255 Pharmacologic Support of the Failing Heart. **2020**, 597-605
- 254 Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. **2021**, 51, e13401 1
- 253 [Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection]. **2020**, 60, 1222 0
- 252 Heart Failure in Diabetes Mellitus: An Updated Review. **2020**, 26, 5933-5952 1
- 251 Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?. **2021**, 36, 211-218
- 250 Classification of heart failure: A farewell to ejection fraction?. **2021**, 25, 2-6
- 249 Exercise in Specific Diseases: Heart Failure with Preserved Ejection Fraction. **2020**, 927-955
- 248 Cardiac Disease in Older Adults. **2020**, 229-249
- 247 Novel treatments for diastolic heart failure. **2020**, 95-127
- 246 Effect of Angiotensin Receptor-Nepriylsin Inhibitor versus Valsartan on Cardiac Status in Patients with Chronic Heart Failure with Reduced Ejection Fraction: A Randomized Clinical Trial in Rangpur Medical College Hospital, Bangladesh. **2020**, 10, 21-34 0
- 245 Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. **2021**, e022859 3
- 244 Treatment Recommendations for Adults with Various Stages of Heart Failure. **2020**, 67, 12-20
- 243 New Evidence about the Beneficial Effects of Angiotensin-Receptor Blockers on the Heart and the Kidney. **2007**, 433-440
- 242 Herzinsuffizienz. **2005**, 1096-1109

- 241 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2006**, 247-276
- 240 Left ventricular systolic and diastolic dysfunction. **2006**, 603-608
- 239 Use of Angiotensin Receptor Blockers in the Elderly. **2005**, 349-367
- 238 Combination Drug Therapy in the Elderly. **2005**, 399-425
- 237 Heart Disease in the Elderly. **2005**, 705-727
- 236 Diabetic Renal and Related Heart Disease. **2006**, 437-451
- 235 Heart Failure Controversies. **2007**, 241-248
- 234 Heart Failure and Sudden Death. **2008**, 873-887
- 233 Treatment of Diastolic Heart Failure. **2008**, 223-239
- 232 Role of Neurohormones and Peripheral Vasculature. **2008**, 71-79
- 231 Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. **2006**, 3, 733-749
- 230 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2007**, 247-272
- 229 Herzinsuffizienz. **2007**, 1225-1239
- 228 ACE-Hemmer und Angiotensinrezeptorantagonisten. **2008**, 207-232
- 227 Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction. **2020**, 120, 831-838 ○
- 226 Does higher SBP at discharge explain better outcomes in non-heart failure with reduced ejection fraction patients? Insights from Fuwai Hospital. **2021**, 39, 356-366
- 225 Stable Ischemic Heart Disease. **2021**, 125-154
- 224 Type 2 Cardiorenal Syndrome. **2021**, 75-94

223	Do antihypertensive agents improve outcomes in patients with congestive heart failure with preserved ejection fraction?. 2020 , Publish Ahead of Print,	
222	No HOPE without proof: do ARBs meet the standard for cardiovascular protection?. 2008 , 10 Suppl, S6	3
221	Cardiac and vascular protection: the potential of ONTARGET. 2008 , 10 Suppl, S7	1
220	Rationale for multiple risk intervention: the need to move from theory to practice. 2007 , 3, 985-97	11
219	Acute pulmonary congestion in patients with systolic heart failure versus diastolic heart failure: experience of a heart emergency unit. 2005 , 13, 208-213	
218	Apoptosis after reperfused myocardial infarction: Role of angiotensin II. 2004 , 9, 219-28	3
217	Heart failure. 2010 , 2010,	1
216	DEFEAT - Heart Failure: a guide to management of geriatric heart failure by generalist physicians. 2009 , 100, 39-50	11
215	Hypokalemia and sudden cardiac death. 2010 , 15, e96-9	67
214	Heart failure. 2011 , 2011,	1
213	Heart failure in elderly: progress in clinical evaluation and therapeutic approach. 2013 , 10, 165-77	9
212	Heart failure with preserved ejection fraction. 2013 , 10, 369-76	14
211	Management of Chronic Heart Failure in Primary Care: What Evidence do we have for Heart Failure with Preserved Systolic Function?. 2010 , 5, 68-76	1
210	Effect of High-dose Telmisartan on the Prevention of Recurrent Atrial Fibrillation in Hypertensive Patients. 2010 , 3, 289	0
209	Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure. 2013 , 6, 740	3
208	Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. 2017 , 60, 71-76	7
207	Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction. 2008 , 1, 323-33	3
206	Heart Failure in Older Adults: A Geriatrician Call for Action. 2018 , 35, S23-S29	

205	Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure. 2020 , 13, 166-174	
204	Encyclopedia of Gerontology and Population Aging. 2021 , 2365-2372	
203	Dysfunction of resolution receptor triggers cardiomyopathy of obesity and signs of non-resolving inflammation in heart failure. 2021 , 542, 111521	
202	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. 2021 , 326, 1919-1929	10
201	Increasing home-time after a first diagnosis of heart failure in Sweden, 20 years trends. 2021 ,	1
200	Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials.. 2021 , 12, 707777	3
199	Diagnostic signature for Heart Failure with Preserved Ejection Fraction (HFpEF): A Machine Learning Approach Using Multi-Modality Electronic Health Record Data.	
198	Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. 2021 , CIRCHEARTFAILURE121008322	2
197	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with acute decompensated heart failure: a systematic review and meta-analysis. 2021 , 1-7	0
196	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. 2021 , 9, 164	1
195	The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. 2021 , 16, e0260554	1
194	Current and future therapeutic perspective in chronic heart failure.. 2021 , 175, 106035	0
193	Heart Failure. 2022 , 103-155	
192	Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy.. 2022 , 20, 21	0
191	Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. 4,	1
190	Behind the Scenes of TOPCAT âBending to Inform. 2022 , 1,	1
189	HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction.. 2021 ,	1
188	A dose-response relationship of renin-angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study.. 2022 ,	3

187	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.. 2022 , 13, 241	0
186	Heart failure with preserved ejection fraction: Squaring the circle between comorbidities and cardiovascular abnormalities.. 2022 ,	1
185	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.. 2022 , 1	1
184	Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure. 2022 , 4, 12	
183	The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes.. 2022 , 111, 460	
182	Hypertension and heart failure with preserved ejection fraction. A past, present, and future relationship.. 2022 , 39, 34-34	0
181	Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older.. 2022 , 1	1
180	Treatment of heart failure with a preserved ejection fraction. 2022 , 65, 18-25	
179	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. 2022 , 24, 4-131	50
178	SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction.. 2022 , 39, 185	0
177	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning.. 2022 , 1	1
176	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. 2021 ,	26
175	Clinical trials report. The sweet secret of dark chocolate. 2004 , 6, 45-6	
174	A Review on CRP Analysis and Obesity Influence in the Disparity of COVID-19 Pandemic. 2022 , 13, 48-55	
173	Heart Failure with Preserved Ejection Fraction. 2022 , 267-287	
172	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity.. 2021 , 12, 785879	0
171	Management of heart failure in older people. 2022 , 52, 72-79	
170	Age and Sex Differences in Heart Failure With Preserved Ejection Fraction. 2022 , 3,	0

169	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure.. 2022,	2
168	Therapeutic targets for cardiac fibrosis: from old school to next-gen.. 2022, 132,	4
167	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy.. 2022, 2022, 3366109	
166	Relation of left atrial overload indices with prognostic endpoints in heart failure and preserved ejection fraction.	0
165	Association between prognosis and the use of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction.	0
164	[Update on diastolic heart failure].. 2022, 1	0
163	Cell Therapy in Heart Failure with Preserved Ejection Fraction.. 2022, 8, e08	1
162	[SEMERGEN positioning on approaching chronic heart failure in primary care].. 2021,	0
161	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,	1
160	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,	15
159	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022, 101161CIR0000000000001063	35
158	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022, 101161CIR0000000000001062	6
157	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,	49
156	Heightened Cardiovascular Risk in Hypertension Associated With Renin-Independent Aldosteronism Versus Renin-Dependent Aldosteronism: A Collaborative Study. 2021, e023082	2
155	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.. 2021,	0
154	Under-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials.. 2021,	0
153	Efficacy of Renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy -from the KUNIUMI Registry Acute Cohort.. 2021,	0
152	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis.. 2021, 100, e28448	0

- 151 [The importance of health-related quality of life at baseline in predicting event-free survival in patients with a cardiovascular risk profile].. **2021**, 67, 361-380 ○
- 150 Hospitalisations in HFpEF: More than just a matter of the heart.. **2021**, e13739
- 149 Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go.. **2021**, 13, e20359 ○
- 148 Essential Therapy for Heart Failure with Preserved Ejection Fraction in 2022. **2022**, 2, 55-63
- 147 SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. **2022**, 2, 67-71
- 146 Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials.. **2022**, ○
- 145 Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. **2022**, 1
- 144 Data_Sheet_1.pdf. **2020**,
- 143 Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.. **2022**, ○
- 142 Signaling cascades in the failing heart and emerging therapeutic strategies.. **2022**, 7, 134 1
- 141 Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin.. **2022**, ○
- 140 20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. **2022**, 9, 149 1
- 139 Management strategies in heart failure with preserved ejection fraction.. **2022**, 1 2
- 138 A Bibliometric Analysis of Heart Failure with Preserved Ejection Fraction From 2000 to 2021.. **2022**, 101243 ○
- 137 New therapies for the treatment of heart failure with preserved ejection fraction.. **2022**, 1
- 136 Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment.. **2022**, 8, 11 ○
- 135 Estimation of Functional Aerobic Capacity Using the Sit-to-Stand Test in Older Adults with Heart Failure with Preserved Ejection Fraction. **2022**, 11, 2692 ○
- 134 Which therapy for which condition?. **2013**, 463-541

133	Heart failure. 2013 , 169-223	5
132	Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines.. 2022 ,	1
131	Mechanical and interventional support for heart failure with preserved ejection fraction: A review.. 2022 ,	0
130	Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD. 2022 , 11, 1657	0
129	Paradigm change in the treatment of chronic heart failure according to ESC Guide 2021: New innovative drugs in focus. 2022 , 47, 40-47	0
128	Angiotensin Receptor-Nepriylsin Inhibitor Attenuates Cardiac Hypertrophy and Improves Diastolic Dysfunction in A Mouse Model of Heart Failure with Preserved Ejection Fraction.	
127	Heart Failure: Future Perspectives. 2022 , 249-256	
126	Pharmacogenomic study of heart failure and candesartan response from the CHARM programme.	0
125	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. 2022 ,	0
124	Cardiorenal Crosstalk in Patients with Heart Failure. 2022 , 2, 369-385	
123	Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021).	0
122	Nonparametric inference of general while-alive estimands for recurrent events.	1
121	Impact of different training modalities on high-density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial.	0
120	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. 2022 , 45,	0
119	Current updates in the pharmacotherapy of heart failure with a preserved ejection fraction. 2022 , 22,	
118	The future of heart failure with preserved ejection fraction.	0
117	Diagnosis and Management of Heart Disease. 2022 , 139-172	
116	Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.	1

115	Positionspapier Herzinsuffizienz und Diabetes.	0
114	Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy. 2022 , 15, 871	
113	Selected Transesophageal Echocardiographic Parameters of Left Ventricular Diastolic Function Predict Length of Stay Following Coronary Artery Bypass Grafting: A Prospective Observational Study. 2022 , 11, 3980	
112	Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. 13,	1
111	Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?. 2022 , 14, 438-445	0
110	A PILOT CLINICAL TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION.	0
109	Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure.	0
108	Positionspapier Herzinsuffizienz und Diabetes.	
107	Clinical impact of blood urea nitrogen, regardless of renal function, in heart failure with preserved ejection fraction. 2022 , 363, 94-101	
106	Insuficiencia cardíaca con función sistólica preservada de etiología infiltrativa. El enemigo silencioso. 2016 , 57-60	
105	The Singapore Heart Failure Risk Score: Prediction of Survival in Southeast Asian Patients. 2019 , 48, 86-94	7
104	Heart failure with preserved ejection fraction—Out with the old and out with the new?. 9,	0
103	Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.	0
102	Prevalence, Presentation, and Outcome of Heart Failure with Preserved Ejection Fraction among Patients Presenting with Undifferentiated Dyspnoea to the Emergency Room: A 10-year Analysis from a Tertiary Centre. 2016 , 45, 18-26	2
101	Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm. 2022 ,	0
100	Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.. 2022 , 62, 3-11	
99	Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes. 2022 , 62, 44-53	2
98	New concepts in heart failure with preserved ejection fraction and hypertension. 2022 , 37, 424-430	

97	Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction. 2022 , 146, 506-518	3
96	Predicting treatment response in patients with HFpEF and myocardial fibrosis. Identifying useful tools with the help of CMR.	
95	Herzinsuffizienz bei Menschen mit Diabetes mellitus. 2022 , 20, 229-236	
94	Efficacy and Safety of Yangyin Shuxin Decoction—Chinese Herbal Medicine Formula For Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial. 2022 , 2022, 1-12	
93	The Efficacy of Various Pharmacological Agents on Long-Term Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Randomized Control Trials. 2022 ,	
92	HEART FAILURE WITH SUPRA-NORMAL LEFT VENTRICLE EJECTION FRACTION: DISTINCT POLYGENIC BASES OF AN UNRECOGNIZED PHENOTYPE.	
91	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. 2022 , 42, 101103	0
90	Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China. 9,	0
89	Novidades e Reflexões sobre o Tratamento Farmacológico da Insuficiência Cardíaca com Fração de Ejeção Preservada. 2022 ,	0
88	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. 2022 , 155, 113701	0
87	CHRONIC HEART DEFICIENCY WITH PRESERVED LEFT VENTRICLE EJECTION FRACTION (literature review). 2012 , 7-11	0
86	Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.	2
85	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction.	1
84	Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. 9,	0
83	Prevalence and incidence of stroke, white matter hyperintensities, and silent brain infarcts in patients with chronic heart failure: A systematic review, meta-analysis, and meta-regression. 9,	1
82	Update on Atrial Shunt Therapy for Treatment of Heart Failure. 2022 , 100090	0
81	Left Ventricular Systolic Dysfunction in Aortic Stenosis: Pathophysiology, Diagnosis, Management, and Future Directions. 2022 , 100089	0
80	From Structural to Functional Hypertension Mediated Target Organ Damage—A Long Way to Heart Failure with Preserved Ejection Fraction. 2022 , 11, 5377	0

- 79 Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. Publish Ahead of Print, ○
- 78 Current Management of Heart Failure with Preserved Ejection Fraction. **2022**, 31, 166-178 ○
- 77 Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure. ○
- 76 Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes. **2022**, 39, 4837-4846 ○
- 75 The Conundrum of HFpEF Definition: Non-Invasive Assessment Uncertainties and Alternative Diagnostic Strategies. **2022**, 101433 ○
- 74 Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. **2022**, 23, 11336 1
- 73 Targets and management of hypertension in heart failure: focusing on the stages of heart failure. **2022**, 24, 1218-1225 ○
- 72 Optimal Treatment for Patients with Heart Failure with Preserved Ejection Fraction. **2022**, 115, 799-799 ○
- 71 Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. **2022**, 40, 473-489 1
- 70 Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. 1
- 69 Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). **2022**, 6-56 ○
- 68 Heart Failure and Diabetes Mellitus: Dangerous Liaisons. **2022**, 4, 163 1
- 67 The Prognostic Value of Neuregulin-1 in Heart Failure Patients With Preserved Ejection Fraction. **2022**, 62, 3-8 ○
- 66 ?????????, ????? ? ??? ????????? ?????????? ?????????? ?????????? ?????????????????? ?????????????? ?????????????? ?????????????? ?????????????? ??????. 22-27 ○
- 65 Heart failure with preserved ejection fraction: Calculating the risk of future heart failure events and death. 9, ○
- 64 The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism. ○
- 63 Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China. 13, ○
- 62 Comorbidities, pharmacologic interventions, and mechanical interventions associated with mortality in isolated diastolic left heart failure: lessons from a national database and a clinical simulator. ○

- 61 Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists. **2022**, 100082 ○
- 60 Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. ○ 2
- 59 Bibliometric and visual analysis of coronary microvascular dysfunction. 9, ○
- 58 Hypertension management in patients with cardiovascular comorbidities. ○
- 57 The EMPEROR—New Clothes: Are We Just Treating Grades of Heart Failure With Reduced Ejection Fraction?. **2022**, 146, 1489-1491 ○
- 56 Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. **2022**, 21, ○
- 55 Combined Neuro-Humoral Modulation and Outcomes in Patients with Chronic Heart Failure and Mildly Reduced or Preserved Ejection Fraction. **2022**, 11, 6627 ○
- 54 Guías de práctica clínica: imprescindibles, pero insuficientes. **2022**, ○
- 53 Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction. ○
- 52 Flowchart for Treatment of Heart Failure with Preserved Ejection Fraction. **2022**, 2, 299-303 ○
- 51 Diastolic Heart Failure: What, So What and Now What?. **2009**, 38, 663-666 ○
- 50 HFpEF: Evidence from Recent Clinical Trials and New Perspectives. **2022**, 2, 326-328 ○
- 49 Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). **2022**, 6-56 ○
- 48 Medical Therapy for Heart Failure with Preserved Ejection Fraction. **2022**, 18, 17-26 ○
- 47 Physical Training in Heart Failure with Preserved Ejection Fraction. **2022**, 2, 310-315 ○
- 46 Renin-angiotensin system inhibitor exerts prognostic effects in HFpEF patients with low baseline chloride level. **2022**, ○
- 45 Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. ○
- 44 Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. ○

43	Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.	0
42	Incident stroke events in clinical trials of antihypertensive drugs in cardiovascular disease patients: A network meta-analysis of randomized controlled trials. 2022 , 101551	0
41	Prognostic Impact of Indeterminate Diastolic Function in Patients with Functionally Insignificant Coronary Stenosis. 2022 ,	0
40	Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data. 2022 , 22,	0
39	Long-term prognostic value of changes in left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction.	0
38	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review.	0
37	The four pillars of HFpEF therapy: is it time to treat heart failure regardless of ejection fraction?. 2022 , 24, L10-L19	0
36	Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?. 2022 ,	0
35	Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest. 2023 , 12, 693	1
34	Heart Failure: A Problem of Our Age. 2011 , 40, 392-393	4
33	Renin-Angiotensin-Aldosterone System as an Old New Target in Heart Failure Therapy. 2023 , 307-330	0
32	Effectiveness of Yiqi Fumai lyophilized injection for acute heart failure: Rationale and design of the AUGUST-AHF cohort study. 9,	0
31	Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis. 2023 , 24, 44-51	0
30	Pharmacotherapies in Heart Failure With Preserved Ejection Fraction. Publish Ahead of Print,	0
29	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. 9,	1
28	Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease-----Balance of efficacy and risk. 14,	0
27	Management of Heart Failure with Reduced Ejection Fraction. 2023 , 101596	0
26	Dapagliflozin in Heart Failure with Preserved Ejection Fraction. 2023 , 388, 286-288	0

- 25 Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. ○
- 24 Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. ○
- 23 A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease. **2023**, 110, 105367 ○
- 22 The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. **2023**, 10, 1314-1325 ○
- 21 The controversial role of beta-blockers in heart failure with preserved ejection fraction. **2023**, 243, 108356 ○
- 20 Effects and Optimal Dose of Exercise on Endothelial Function in Patients with Heart Failure: A Systematic Review and Meta-Analysis. **2023**, 9, ○
- 19 Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety. **2023**, ○
- 18 Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors. **2023**, 147, 635-637 ○
- 17 In Search of the Holy Grail: Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved Ejection Fraction. **2023**, 24, 4903 ○
- 16 Sudden Death in Men Versus Women with Heart Failure. **2023**, 20, 129-137 ○
- 15 Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure with Preserved Ejection Fraction. **2023**, ○
- 14 Discriminative Role of Invasive Left Heart Catheterization in Patients Suspected of Heart Failure With Preserved Ejection Fraction. ○
- 13 The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis. ○
- 12 Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. **2023**, 10, 114 ○
- 11 Heart Failure With Preserved Ejection Fraction. **2023**, 329, 827 ○
- 10 Hemodynamic Evaluation of a Centrifugal Left Atrial Decompression Pump for Heart Failure with Preserved Ejection Fraction. **2023**, 10, 366 ○
- 9 Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction. **2023**, ○
- 8 Heart Failure with Preserved Ejection Fraction. **2023**, 89-106 ○

- 7 Heart failure: pathophysiology and the emergence of novel therapies. **2023**, 441-458 ○
- 6 Event Adjudication Is Unnecessary in Blinded Trials and May Be Detrimental. **2023**, 11, 422-424 ○
- 5 Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Chronic Heart Failure. 2, ○
- 4 Updates in Cardiorenal Syndrome. **2023**, ○
- 3 Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. **2023**, 229-264 ○
- 2 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. **2023**, ○
- 1 Diastolic heart failure: 20 years later. Current issues of pathogenesis, diagnosis and treatment of heart failure with preserved LVEF. **2023**, 63, 3-12 ○